The present disclosure generally relates to methods for measuring biochemical reactions and analysis of reaction products. More specifically, the present disclosure relates to methods for characterizing a biochemical reaction and analysis of reaction products by controlling dispersion of reagents within fluid streams such that the measuring of the biochemical reaction is substantially free of a measurable dispersion artifact.
Biochemical and biological assays are a primary tool utilized in many aspects of drug discovery, including but not limited to (1) fundamental research in biochemistry and biology to describe novel phenomena, (2) analysis of large numbers of compounds, (3) screening of compounds, (4) clinical tests applied during clinical trials, and (5) even diagnostic tests during administration of drugs. Many biological and biochemical assays require measurement of the response of a biological or biochemical system to different concentrations of one reagent, such as an inhibitor, an activator, a substrate, or an enzyme. Typically, discrete steps of biochemical concentration are mixed within a prescribed range. The number of concentrations measured is limited by the number of dilution steps, which are limited in practice by the time and effort required to make the discrete dilutions, by the time and effort to process the resulting individual reactions, by reagent consumption as the number of reactions increases, and more strictly by pipetting errors that limit the resolution of discrete steps.
As technology advances in drug development, miniaturization and automation are active areas of innovation, with primary drivers being decreased cost (through decreased reagent use and decreased manpower) and improved data quality (through finer process control and increased process reliability). Improvements in data quality and automation frequently convey additional advantages that permit new scientific approaches to questions. Automation, if sufficiently extensive, can include software that permits automatic work scheduling to improve efficiency or statistical process control for process improvement. Again, these improvements achieve greater reliability, use less manpower, and improve throughput.
Microfluidic systems, including labs-on-a-chip (LoCs) and micro-total analysis systems (μ-TAS), are currently being explored as an alternative to conventional approaches that use microtiter plates. The miniaturization afforded by microfluidic systems has the potential to greatly reduce the amount of reagent needed to conduct high-throughput screening. Thus far, commercial microfluidic systems have shown some promise in performing point measurements, but have not been employed to mix concentration gradients and particularly continuous gradients due to technologic limitations. In particular, several challenges remain in the design of industry-acceptable microfluidic systems. Apart from cost and manufacture related issues, many sources of such challenges relate to the fact that, in a micro-scale or sub-micro-scale environment, certain fluid characteristics such as viscosity, surface tension, shear resistance, thermal conductivity, electrical conductivity, molecular diffusivity, and the like, take on a much more dominant role than other, more easily manageable factors such as weight and gravity. In addition, controlling the signal-to-noise ratio becomes much more challenging when working with nano-scale volumes and flow rates, as certain sources of noise, such as for example noise related to dispersion characteristics of reagents within the reaction mixture, that typically are inconsequential in macroscopic applications now become more noticeable and thus deleterious to the accuracy of data acquisition instruments.
Thus, it would be desirable to analyze biochemical and biological systems using assays that employ continuous gradients so as to achieve higher quality data with less noise in the data, such as measurable dispersion artifact, in a shorter time frame and using fewer reagents than present methods.
According to one embodiment, a method for measuring a biochemical reaction is provided. In some embodiments, the method comprises flowing a first fluid stream comprising a first reagent into contact with a second fluid stream comprising a second reagent so as to merge the first and second fluid streams into a first merged fluid stream; contacting the first and second reagents with a third reagent by flowing a third fluid stream comprising the third reagent into contact with the first merged fluid stream so as to merge the first merged fluid stream and the third fluid stream into, a second merged fluid stream, wherein the biochemical reaction occurs between the first, second and third reagents within the second merged fluid stream; determining an outcome of contacting the first, second and third reagents within the second merged fluid stream in order to measure the biochemical reaction; and controlling dispersion of the first, second, and third reagents within the second merged fluid stream such that the measuring of the biochemical reaction is substantially free of a measurable dispersion artifact.
In some embodiments, controlling dispersion of the first, second, and third reagents comprises flowing the first merged fluid stream through a mixing region to laterally mix the fluid streams and passing the merged, laterally mixed first fluid stream through a controlled dispersion element to axially disperse the first and second reagents within the first merged fluid stream. In some embodiments, the mixing region comprises a microfluidic mixing channel sufficiently narrow and long to permit lateral mixing by diffusion. Further, in some embodiments, the controlled dispersion element is in flow communication with the mixing channel. Still further, in some embodiments, the controlled dispersion element is an expansion channel, and in some embodiments, the expansion channel has a cross-sectional area between approximately 10 to 1000 times the cross-sectional area of the mixing channel. Still further, in some embodiments, the controlled dispersion element is adapted for passage of the first merged fluid stream through the controlled dispersion element such that axial dispersion of the gradient after the controlled dispersion element is less than the axial dispersion within the controlled dispersion element. In some embodiments, the controlled dispersion element comprises an in-line filter unit. In some embodiments, the first and second fluid streams flow within fluid tubes and the controlled dispersion element comprises a union of tubing that provides variation in effective fluid tube diameter and in some other embodiments, the first and second fluid streams flow within fluid channels and the controlled dispersion element comprises an elongated section of a fluid channel.
In some other embodiments, controlling dispersion of the first, second, and third reagents comprises controlling flow rates of the first and second fluid streams to create a concentration gradient that is substantially free of a measurable dispersion artifact. Further, in some embodiments, the concentration gradient is substantially free of the measurable dispersion artifact during at least a time between forming the second merged fluid stream and determining the outcome of contacting the first, second, and third reagents within the second merged stream. Still further, in some embodiments, a concentration gradient is created for the first and second reagents through controlled variation of volumetric flow rates of the first and second fluid streams.
In some embodiments, a concentration gradient for the first and second reagents is created through controlled variation of volumetric flow rates of the first and second fluid streams, and in some embodiments, the concentration gradient is a continuous concentration gradient. Further, in some embodiments, the continuous concentration gradient is formed by varying the volumetric flow rates of the first and second fluid streams within a continuous-flow reaction system.
In some embodiments, the first, second, and third fluid streams are driven by a first, second, and third pump, respectively, which can be displacement pumps. In some embodiments, varying volumetric flow rate of the first and second fluid streams comprises controlling speeds of the first pump and the second pump, respectively. Further, the first and second pumps can be synchronized to maintain an overall constant volumetric flow rate while varying individual volumetric flow rates of the first and second fluid streams. Still further, the volumetric flow rate of the third pump can be constant and in some embodiments, the combined volumetric flow rate of the three pumps can be constant.
In some embodiments, the continuous-flow reaction system is a fluidic system comprising a network of tubing in flow communication.
In some embodiments, determining the outcome of the biochemical reaction comprises utilizing a sample processing apparatus. The sample processing apparatus can comprise in some embodiments a microfluidic chip, wherein the first, second, and third fluid streams flow within channels on the microfluidic chip. For example, in some embodiments, the first fluid stream flows within a first input channel and the second fluid stream flows within a second input channel, and wherein the contacting between the first and second fluid streams to form the merged fluid stream occurs at a merge region where the first and second channels intersect. Further, in some embodiments, the sample processing apparatus can comprise an excitation source, at least one wavelength selector, a radiation detector, and a signal processing and readout device. Still further, in some embodiments, the sample processing apparatus comprises a thermal control unit for regulating the temperature of the reagents.
In some embodiments of the method, measuring the biochemical reaction can be selected from the group consisting of steady-state kinetic constants, binding constants for ligands (Kd), capacity of receptor binding (Bmax), kinetic mechanisms of enzyme reactions, effects of reagent components on reagent kinetics, kinetic isotope effect on enzyme catalyzed reactions, pH effects on reagent kinetics, dose-response of one reagent on kinetic properties of another reagent (IC50 and EC50), and combinations thereof.
Further, in some embodiments of the presently disclosed subject matter, a microfluidic device is provided. The microfluidic device comprises in some embodiments a first mixing junction adapted to receive a first fluid stream and a second fluid stream and providing an area for the first and second fluid streams to merge into a first fluid mix; a controlled dispersion element having in fluid communication a first end and a second end, wherein the first end is in fluid communication with the first mixing junction for passage of the first fluid mix through the controlled dispersion element to produce a dispersed fluid mix at the second end; and a second mixing junction in fluid communication with the second end of the controlled dispersion element and adapted to receive the dispersed fluid mix and a third fluid stream, the second mixing junction providing an area for the third fluid stream to merge with the dispersed fluid mix.
Therefore, it is an object to provide methods for measuring a biochemical reaction.
An object having been stated hereinabove, and which is achieved in whole or in part by the present disclosure, other objects will become evident as the description proceeds when taken in connection with the accompanying drawings as best described hereinbelow.
b is a graph showing a simulation for characterization of bisubstrate kinetic mechanisms using a second method and equation;
Noise in a fluid mix concentration or poor mixing of constituents can result in poor data quality in biochemical reaction systems, including for example, microfluidic systems. This poor data quality is typically observed as a random series of locally steep concentration gradients in the mixed fluids, which produces a measurable dispersion artifact. The presently disclosed subject matter provides methods for improving data quality, including reducing dispersion artifact, through controlling dispersion of reagents within the biochemical reaction. For example, steep concentration gradients can be reduced via molecular diffusion and dispersion. In a microfluidic system, for example, molecular diffusion and dispersion can occur as a fluid advances through a microscale channel. Diffusion and dispersion transport the fluid from regions of high concentration to regions of low concentration, occur whenever the concentration gradient is non-zero, and decrease the magnitude of the concentration gradient.
Diffusion in the axial direction of, for example, a microfluidic channel can be seemingly greater than expected from molecular diffusion. This is because microfluidic channels have a parabolic velocity profile that is typical for laminar flow in a tube—the axial velocity is maximal and the velocity at the wall is zero. Thus, a concentration gradient experiences dispersion arising from both molecular diffusion and from distortion of the gradient by the velocity profile, a phenomenon called Taylor-Aris dispersion. Although not intending to be bound by theory, the chemical, therefore, appears to have a different axial diffusion coefficient, D′, provided by the following equation:
wherein DC is the diffusion coefficient, r is the radius of the channel, and V is the average velocity.
Referring to
Accordingly, the presently disclosed subject matter provides a method for measuring a biochemical reaction such that the measured reaction data is substantially free of a measurable dispersion artifact. In some embodiments, the method comprises flowing a first fluid stream comprising a first reagent into contact with a second fluid stream comprising a second reagent so as to merge the first and second fluid streams into a first merged fluid stream; contacting the first and second reagents with a third reagent by flowing a third fluid stream comprising the third reagent into contact with the first merged fluid stream so as to merge the first merged fluid stream and the third fluid stream into a second merged fluid stream, wherein the biochemical reaction occurs between the first, second and third reagents within the second merged fluid stream; determining an outcome of contacting the first, second and third reagents within the second merged fluid stream in order to measure the biochemical reaction; and controlling dispersion of the first, second, and third reagents within the second merged fluid stream such that the measuring of the biochemical reaction is substantially free of a measurable dispersion artifact.
In some embodiments, a concentration gradient for the first and second reagents is created through controlled variation of volumetric flow rates of the first and second fluid streams, and in some embodiments, the concentration gradient is a continuous concentration gradient. Further, in some embodiments, the continuous concentration gradient is formed by varying the volumetric flow rates of the first and second fluid streams within a continuous-flow reaction system.
In some embodiments, the first, second, and third fluid streams are driven by a first, second, and third pump, respectively, which can be displacement pumps. Further detailed description of displacement pumps useful with the presently disclosed methods is provided herein below. In some embodiments, varying volumetric flow rate of the first and second fluid streams comprises controlling speeds of the first pump and the second pump, respectively. Further, the first and second pumps can be synchronized to maintain an overall constant volumetric flow rate while varying individual volumetric flow rates of the first and second fluid streams. Still further, the volumetric flow rate of the third pump can be constant and in some embodiments, the combined volumetric flow rate of the three pumps can be constant. Additional detailed description of controlling pump speeds and flow rates in accordance with the presently disclosed methods is provided herein below.
In some embodiments, the continuous-flow reaction system is a fluidic system comprising a network of tubing in flow communication. In some embodiments the continuous-flow reaction system is a fluidic system comprising a microfluidic chip.
In some embodiments, determining the outcome of the biochemical reaction comprises utilizing a sample processing apparatus. The sample processing apparatus can comprise in some embodiments a microfluidic chip, wherein the first, second, and third fluid streams flow within channels on the microfluidic chip. For example, in some embodiments, the first fluid stream flows within a first input channel and the second fluid stream flows within a second input channel, and wherein the contacting between the first and second fluid streams to form the merged fluid stream occurs at a merge region where the first and second channels intersect. Further, in some embodiments, the sample processing apparatus can comprise an excitation source, at least one wavelength selector, a radiation detector, and a signal processing and readout device. Still further, in some embodiments, the sample processing apparatus comprises a thermal control unit for regulating the temperature of the reagents. Further detailed description related to exemplary sample processing apparatuses and microfluidic chips is provided herein below.
In some embodiments of the method, measuring the biochemical reaction can be selected from the group consisting of steady-state kinetic constants, binding constants for ligands (Kd), capacity of receptor binding (Bmax), kinetic mechanisms of enzyme reactions, effects of reagent components on reagent kinetics, kinetic isotope effect on enzyme catalyzed reactions, pH effects on reagent kinetics, dose-response of one reagent on kinetic properties of another reagent (IC50 and EC50), and combinations thereof. Additional exemplary embodiments of biochemical reactions that can be measured using the presently disclosed methods are described herein below.
I. A. Methods for Controlling Dispersion Using Controlled Dispersion Elements
In some embodiments of the presently disclosed subject matter, controlling dispersion of reagents in a biochemical reaction comprises flowing a first merged fluid stream comprising at least first and second reagents through a mixing region to laterally mix the fluid streams and then passing the merged, laterally mixed first merged fluid stream through a controlled dispersion element to axially disperse the at least first and second reagents within the first merged fluid stream. In some embodiments, the mixing region comprises a microfluidic mixing channel sufficiently narrow and long to permit lateral mixing by diffusion.
Further, in some embodiments, the controlled dispersion element is in flow communication with the mixing channel. Still further, in some embodiments, the controlled dispersion element is an expansion channel, and in some embodiments, the expansion channel has a cross-sectional area between approximately 10 to 1000 times the cross-sectional area of the mixing channel. Exemplary expansion channels useful with the presently disclosed methods are discussed in detail herein below. Still further, in some embodiments, the controlled dispersion element is adapted for passage of the first merged fluid stream through the controlled dispersion element such that axial dispersion of the gradient after the controlled dispersion element is less than the axial dispersion within the controlled dispersion element.
In some embodiments, the controlled dispersion element comprises an in-line filter unit. In some embodiments, the first and second fluid streams flow within fluid tubes and the controlled dispersion element comprises a union of tubing that provides variation in effective fluid tube diameter. In some other embodiments, the first and second fluid streams flow within fluid channels, such as for example fluid channels within a microfluidic chip, and the controlled dispersion element comprises an elongated section of a fluid channel.
Specific channel geometries, referred to herein as controlled dispersion elements, can facilitate diffusion and dispersion that strongly dissipate steeper concentration gradients—the higher spatial frequency components contributed by noise, which can create dispersion artifact—while having only small effects on the shallower gradients—the lower spatial frequency components of the desired gradient. It is, therefore, possible to use the geometries to filter out noise associated with mechanical instabilities. For example, the “racetrack” effect caused by a fluid advancing through a curved channel can provide increased dispersion. Additionally, for example, controlled dispersion elements such as channel expanders and reducers can provide increased dispersion.
An expander is a channel section where the cross-sectional area of the channel increases in the direction of fluid flow. A reducer is a channel section where the cross-sectional area of the channel decreases in the direction of fluid flow. An expander can be followed downstream by a reducer to form an expansion channel, as described in more detail below. Additionally, outpockets of channels can increase dispersion by creating local regions where the fluid is nearly stagnant. As fluid of differing concentration flows past these outpockets, diffusion between slower moving fluid in the outpocket and the passing fluid near the center of the channel causes dispersion of concentration gradients. For example, consider the case in which fluid of low concentration moves down the channel and fills the outpockets. If a fluid of higher concentration next moves down the channel, then diffusion into the low concentration fluid in the outpocket can decrease the concentration nearer the center of the channel, decreasing the magnitude of the concentration at the center. Again, if a fluid of lower concentration now follows, diffusion out of the outpockets will elevate the concentration nearer the channel center. The total result is that oscillation in axial concentration gradients are reduced, with higher spatial frequencies being affected more strongly. These specific channel geometries can be formed at sections of a microfluidic chip, such as chip 102 shown in
A controlled dispersion element in the form of a channel including one or more curved sections, such as a serpentine channel, can be used for diffusing and dispersing locally steep concentration gradients to dissipate noise in a fluid mix concentration. As stated above, the rate of dispersion can be increased by the “racetrack” effect, which can occur as a fluid advances through a curved channel section.
Serpentine channel 402 can be positioned immediately downstream from mixing region 412 to disperse noise in the concentration gradient immediately after mixing. In this embodiment, serpentine channel 402 has a length of 10 centimeters and a cross-sectional area of 500 square micrometers. Alternatively, serpentine channel can have a length between approximately 0.1 and approximately 500 centimeters and a cross-sectional area between approximately 10 and 100,000 square micrometers. Serpentine channel 402 can disperse the noise generated by any type of mechanical instability, such as the noise in the fluid flow originating upstream from serpentine channel 402. Channels that are longer and have more turns can more completely decrease noise in a concentration gradient, with the noise decreasing continuously along the length of the channel.
As stated above, noise in the concentration of fluid mixtures can also be reduced by a variety of controlled dispersion elements, including for example, expansion channels. When fluid flows through an expansion channel, noise in the fluid flow is reduced by dispersion. Dispersion can be increased by increasing the cross-sectional area of the expansion channel with respect to the channels connecting to the expansion channel, as described above in the equation for Taylor-Aris dispersion. A portion of a channel having an expansion or contraction of the cross-sectional area in the direction of fluid flow can increase dispersion.
Expansion channels can be shaped and sized for introducing a desired amount of dispersion over a predetermined spatial frequency. For example, an expansion channel acts as a low-pass filter and can be shaped and sized to possess selected cut-off frequency and decay. A channel possessing an expansion channel filter will filter only the region of the gradient that is in the filter and, thus, only the desired spatial frequency.
A similar filtering effect can be introduced by placing small outpockets along the wall of the microfluidic channel. Outpockets can be considered as small expansion channels placed in series.
Expansion channels, such as expansion channels 802 and 902 of
Dispersion of different components in a mixing and reacting flow can lead to unexpected systematic errors in measurements of the reaction. Referring to
In one instance, the concentration gradient generated at junction 2008 can have an analyte with a higher diffusivity than other components in the fluids. For example, the analyte is a low molecular weight inhibitor of an enzymatic reaction, with the enzyme being introduced in fluid F. The higher diffusivity of the inhibitor can cause it to disperse more rapidly than the enzyme. The result of this differential dispersion of components of the reaction is that the concentration of the inhibitor in a parcel of fluid traveling down aging loop 2012 varies over time. The concentrations of various components, including products of reactions, can be measured at detection point 2014.
Referring to
This change in the concentration of the inhibitor over time can complicate many analyses. For example, in many analyses of enzyme behavior, the concentrations of components of the reaction are assumed to be constant throughout the reaction. The differential dispersion of the inhibitor, or any other low molecular weight species, such as a substrate, violates the assumption of constant concentration, and introduces errors into subsequent analyses. Differential dispersion of components can be greatly reduced by introducing dispersion into the gradient formed at junction 2008 but before it combines with fluid F at junction 2010. This can be accomplished through the incorporation of controlled dispersion elements, as exemplified in
Referring to
Referring to
Another way to present these concepts is in
Referring now to
The purpose of a controlled dispersion element, such as the expansion channel 2116 in microfluidic chip 2100 in
I.B. Methods for Controlling Dispersion BY Controlling Flow Rates of Fluid Streams Comprising Reaction Reagents
In some embodiments of the presently disclosed subject matter, controlling dispersion of reagents in a biochemical reaction comprises controlling synchronistically flow rates of a first fluid stream comprising at least a first reagent and a second fluid stream comprising at least a second reagent to, create a concentration gradient that is substantially free of a measurable dispersion artifact. In other words, it is possible to mix a gradient in a microfluidic chip that does not have a controlled dispersion element, such as microfluidic chip 2000 in
Referring now to
Pumps under computer control, for example, could generate gradients such as shown by plot AA300. Computer control of pump speed to generate concentration gradients permits the formation of arbitrary gradients, allowing control of dispersion via a range of gradient shapes. Note, however, that any noise in gradient AA300, or any other pump-generated gradient, might not be filtered as effectively as when passing through a controlled dispersion element such as expansion channel 2016 in microfluidic chip 2100.
Exemplary microfluidic chips, systems, and related methods are described herein below for measuring biochemical reactions and generating continuous concentration gradients of reagents for use with the presently disclosed novel methods. In some embodiments, the microfluidic systems described herein incorporate improvements for reducing or eliminating noise in the fluid mix concentration, which can result in measurable dispersion artifact, and for improving rapid diffusion and dispersion or reagents in the fluid stream. These microfluidic chips, systems, and methods are described with regard to the accompanying drawings. It should be appreciated that the drawings pertaining to particular embodiments do not constitute limitations on the scope of the disclosed microfluidic chips, systems, and methods.
As used herein, the term “microfluidic chip,” “microfluidic system,” or “microfluidic device” generally refers to a chip, system, or device which can incorporate a plurality of interconnected channels or chambers, through which materials, and particularly fluid borne materials can be transported to effect one or more preparative or analytical manipulations on those materials. A microfluidic chip is typically a device comprising structural or functional features dimensioned on the order of mm-scale or less, and which is capable of manipulating a fluid at a flow rate on the order of μl/min or less. Typically, such channels or chambers include at least one cross-sectional dimension that is in a range of from about 1 μm to about 500 μm. The use of dimensions on this order allows the incorporation of a greater number of channels or chambers in a smaller area, and utilizes smaller volumes of reagents, samples, and other fluids for performing the preparative or analytical manipulation of the sample that is desired.
Microfluidic systems are capable of broad application and can generally be used in the performance of biological and biochemical analysis and detection methods. The systems described herein can be employed in research, diagnosis, environmental assessment and the like. In particular, these systems, with their micron scales, nanoliter volumetric fluid control systems, and integratability, can generally be designed to perform a variety of fluidic operations where these traits are desirable or even required. In addition, these systems can be used in performing a large number of specific assays that are routinely performed at a much larger scale and at a much greater cost.
A microfluidic device or chip can exist alone or may be a part of a microfluidic system which, for example and without limitation, can include: pumps for introducing fluids, e.g., samples, reagents, buffers and the like, into the system and/or through the system; detection equipment or systems; data storage systems; and control systems for controlling fluid transport and/or direction within the device, monitoring and controlling environmental conditions to which fluids in the device are subjected, e.g., temperature, current and the like.
As used herein, the term “channel” or “microfluidic channel” can mean a cavity formed in a material by any suitable material removing technique, or can mean a cavity in combination with any suitable fluid-conducting structure mounted in the cavity such as a tube, capillary, or the like.
As used herein, the term “reagent” generally means any flowable composition or chemistry. The result of two reagents merging or combining together is not limited to any particular response, whether a biological response or biochemical reaction, a dilution, or otherwise.
In referring to the use of a microfluidic chip for handling the containment or movement of fluid, the terms “in”, “on”, “into”, “onto”, “through”, and “across” the chip generally have equivalent meanings.
As used herein, the term “communicate” (e.g., a first component “communicates with” or “is in communication with” a second component) and grammatical variations thereof are used herein to indicate a structural, functional, mechanical, electrical, optical, or fluidic relationship, or any combination thereof, between two or more components or elements. As such, the fact that one component is said to communicate with a second component is not intended to exclude the possibility that additional components may be present between, and/or operatively associated or engaged with, the first and second components.
As used herein, the terms “measurement”, “sensing”, and “detections” and grammatical variations thereof have interchangeable meanings; for the purpose of the present disclosure, no particular distinction among these terms is intended.
Embodiments disclosed herein comprise hardware and/or software components for controlling liquid flows in microfluidic devices and measuring the progress of miniaturized biochemical reactions occurring in such microfluidic devices. As the description proceeds, it will become evident that the various embodiments disclosed herein can be combined according to various configurations to create a technologic system or platform for implementing micro-scale or sub-micro-scale analytical functions. One or more of these embodiments can contribute to or attain one or more advantages over prior art technology, including: (1) 1000-fold reduction in the amount of reagent needed for a given assay or experiment; (2) capability of generating continuous concentration gradients between reagents and subsequent elimination of the need for disposable assay plates; (3) fast, serial processing of independent reactions; (4) data readout in real-time; (5) improved data quality; (6) more fully integrated software and hardware, permitting more extensive automation of instrument function, 24/7 operation, automatic quality control and repeat of failed experiments or bad gradients, automatic configuration of new experimental conditions, and automatic testing of multiple hypotheses; (7) fewer moving parts and consequently greater robustness and reliability; and (8) simpler human-instrument interface. As the description proceeds, other advantages may be recognized by persons skilled in the art.
Referring now to
Referring to
In one exemplary yet non-limiting embodiment, pump barrel 22 is a gas-tight micro-syringe type, having a volume ranging from approximately 10-250 μl. The thread pitch of lead screw 14 can be approximately 80 threads per inch. Gear reduction device 16 produces a gear reduction of 1024:1 or thereabouts. Servo motor 12 and gear reduction device 16 can have an outside diameter of 10 mm or thereabouts. Servo motor 12 uses a 10-position magnetic encoder with quadrature encoding that provides forty encoder counts per revolution, and the resolution is such that each encoder count is equivalent to 0.0077 μm of linear displacement. The foregoing specifications for the components of pump P can be changed without departing from the scope of the embodiment.
In some embodiments for which a plurality of pumps are provided (e.g., pumps PA-PC in
The ability to produce very low flow-rate, stable displacement flows to generate concentration gradients, believed to be 3-4 orders of magnitude slower than that heretofore attainable, provides a number of advantages. Chips can be fabricated from any material, and surface chemistry does not need to be carefully controlled, as with electro-osmotic pumping. Any fluid can be pumped, including fluids that would be problematic for electro-osmotic flows (full range of pH, full range of ionic strength, high protein concentrations) and for pressure driven flows (variable viscosities, non-Newtonian fluids), greatly simplifying the development of new assays. Variations in channel diameters, either from manufacture variability or from clogging, do not affect flow rates, unlike electro-osmotic or pressure flows. Computer control and implementation of control (sensors and actuators) are simpler than for pressure flows, which require sensors and actuators at both ends of the channel. Displacement-driven flows provide the most-straightforward means for implementing variable flows to generate concentration gradients.
The ability to pump at ultra-low flow rates (nl/min) provides a number of advantages in the operation of certain embodiments of microfluidic chip MFC and related methods disclosed herein. These low flow rates enable the use of microfluidic channels with very small cross-sections. Higher, more conventional flow rates require the use of longer channels in order to have equivalent residence times (required to allow many biochemical reactions or biological responses to proceed) or channels with larger cross-sectional areas (which can greatly slow mixing by diffusion and increase dispersion of concentration gradients). In addition, reagent use is decreased because, all other parameters being equal, decreasing the flow rate by half halves the reagent use. Smaller channel dimensions (e.g., 5-30 μm) in the directions required for diffusional mixing of reagents permits even large molecules to rapidly mix in the microfluidic channels.
Referring back to
Suitable examples of such a microfluidic chip MFC are disclosed in co-pending, commonly owned U.S. Provisional Applications entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING DIFFUSION AND COMPLIANCE EFFECTS AT A FLUID MIXING REGION, U.S. Provisional Application No. 60/707,220 (Attorney Docket No. 447/99/3/1); MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING NOISE GENERATED BY MECHANICAL INSTABILITIES, U.S. Provisional Application No. 60/707,245 (Attorney Docket No. 447/99/3/2); MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING BACKGROUND AUTOFLUORESCENCE AND THE EFFECTS THEREOF, U.S. Provisional Application No. 60/707,386 (Attorney Docket No. 447/99/3/3); and MICROFLUIDIC CHIP APPARATUSES, SYSTEMS, AND METHODS HAVING FLUIDIC AND FIBER OPTIC INTERCONNECTIONS, U.S. Provisional Application No. 60/707,246 (Attorney Docket No. 447/99/4/2) the contents of which are incorporated herein in their entireties. As discussed therein, to provide internal channels, microfluidic chip MFC can comprise two body portions such as plates or layers, with one body portion serving as a substrate or base on which features such as channels are formed and the other body portion serving as a cover. The two body portions can be bonded together by any means appropriate for the materials chosen for the body portions. Non-limiting examples of bonding techniques include thermal bonding, anodic bonding, glass frit bonding, adhesive bonding, and the like. Non-limiting examples of materials used for the body portions include various structurally stable polymers such as polystyrene, metal oxides such as sapphire (Al2O3), silicon, and oxides, nitrides or oxynitrides of silicon (e.g., SixNy, glasses such as SiO2, or the like). In advantageous embodiments, the materials are chemically inert and biocompatible relative to the reagents to be processed, or include surfaces, films, coatings or are otherwise treated so as to be rendered inert and/or biocompatible. The body portions can be constructed from the same or different materials. To enable optics-based data encoding of analytes processed by microfluidic chip MFC, one or both body portions can be optically transmissive or include windows at desired locations. The channels can be formed by any suitable micro-fabricating techniques appropriate for the materials used, such as the various etching, masking, photolithography, ablation, and micro-drilling techniques available. The channels can be formed, for example, according to the methods disclosed in a co-pending, commonly owned U.S. Provisional Application entitled MICROFLUIDIC CHIP APPARATUSES, SYSTEMS, AND METHODS HAVING FLUIDIC AND FIBER OPTIC INTERCONNECTIONS, U.S. Provisional Application No. 60/707,246 (Attorney Docket No. 447/99/4/2), the content of which is incorporated herein in its entirety. In some embodiments, the size of the channels can range from approximately 5 to 500 μm in cross-sectional area.
As shown in
First input channel ICA and second input channel ICB terminate or meet at a first T-junction or merging point MP1. From first merging point MP1, a first mixing channel MC1 traverses through microfluidic chip MFC over a distance sufficient to enable passive mixing of reagents RA and RB introduced by first input channel ICA and second input channel ICB. In some embodiments, the mechanism for passive mixing is thermal or molecular diffusion that depends on flow velocity (e.g. time of flight) and distance of travel. Accordingly, microfabricated active mixers, which can be a source of noise, complexity, unreliability and cost, are not required but could be provided. In the present exemplary embodiment, third input channel ICC and first mixing channel MC1 terminate or meet at a second T-junction or merging point MP2, from which a second mixing channel MC2 traverses through microfluidic chip MFC over a distance sufficient for mixing.
Second mixing channel MC2 communicates with a process/reaction channel or aging loop AL. Aging loop AL has a length sufficient for prosecuting a reaction or other interaction between reagents after the reagents have been introduced in two or more of first input channel ICA, second input channel ICB and/or third input channel ICC, merged at first mixing point MP1 and/or second mixing point MP2, and thereafter mixed in first mixing channel MC1 and/or second mixing channel MC2. For a given area of microfluidic chip MFC, the length of aging loop AL can be increased by providing a folded or serpentine configuration as illustrated in
As further illustrated in
After an experiment has been run and data have been acquired, the reaction products flow from aging loop AL to any suitable off-chip waste site or receptacle W. Additional architectural details and features of microfluidic chip MFC are disclosed in co-pending, commonly owned U.S. Provisional Applications entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING DIFFUSION AND COMPLIANCE EFFECTS AT A FLUID MIXING REGION, U.S. Provisional Application No. 60/707,220 (Attorney Docket No. 447/99/3/1); MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING NOISE GENERATED BY MECHANICAL INSTABILITIES, U.S. Provisional Application No. 60/707,245 (Attorney Docket No. 447/99/3/2); MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING BACKGROUND AUTOFLUORESCENCE AND THE EFFECTS THEREOF, U.S. Provisional Application No. 60/707,386 (Attorney Docket No. 447/99/3/3); and MICROFLUIDIC CHIP APPARATUSES, SYSTEMS, AND METHODS HAVING FLUIDIC AND FIBER OPTIC INTERCONNECTIONS, U.S. Provisional Application No. 60/707,246 (Attorney Docket No. 447/99/4/2), the contents of which are incorporated in their entireties.
An example of a method for generating and mixing concentration gradients using sample processing apparatus SPA illustrated in
Once sample processing apparatus SPA has been prepared, concentration gradients can be run through microfluidic chip MFC. Two or more of pumps PA, PB and/or PC are activated to establish separate flows of different reagents RA, RB and/or RC into microfluidic chip MFC for combination, mixing, reaction, and measurement. A variety of combining strategies can be employed, depending on the number of inputs into microfluidic chip MFC and the corresponding number of pumps PA-PC, on their sequence of mixing determined by the geometry of fluidic channels in microfluidic chip MFC, and on the sequence of control commands sent to the pumps PA-PC. Using a microfluidic chip MFC with three inputs as illustrated in
In accordance with one embodiment of the method, the total or combined volumetric flow rate established by the active pumps PA, PB and/or PC can be maintained at a constant value during the run, in which case the transit time from mixing to measurement is constant and, consequently, the duration of reaction is held constant. In addition, the ratio of the individual flow rates established by respective pumps PA, PB and/or PC can be varied over time by individually controlling their respective servo motors 12, thereby causing the resulting concentration gradient of the mixture in aging loop AL to vary with time (i.e. concentration varies with distance along aging loop AL). The concentration gradient of interest is that of the analyte relative to the other components of the mixture. The analyte can be any molecule of interest, and can be any form of reagent or component. Non-limiting examples Include inhibitors, substrates, enzymes, fluorophores or other tags, and the like. As the reaction product passes through detection point DP with a varying concentration gradient, the detection equipment samples the reaction product flowing through according to any predetermined interval (e.g., 100 times per second). The measurements taken of the mixture passing through detection point DP can be temporally correlated with the flow ratio produced by pumps PA, PB and/or PC, and a response can be plotted as a function of time or concentration.
Referring to
In addition to the methods previously described herein above, sample processing apparatus SPA is useful for a wide variety of applications, due at least in part to the simplicity of the technique for concentration gradient mixing described hereinabove and the ubiquity of concentration gradients in assays. Non-limiting examples of applications include enzyme kinetics, clinical diagnostics for neo-natal care (e.g., blood enzyme diagnostics with microliter samples), toxicity studies for drug development (e.g., P450 assays or S9 fraction assays), flow cytometry, cell-based assays, and gradient elution for mass spectrometry.
Exemplary enzymological variables and measurements that can be analyzed and prepared include, but are not limited to:
(1) basic steady-state kinetic constants, such as Michaelis constants for substrates (Km), maximum velocity (Vmax), and the resultant specificity constant (Vmax/Km or kcat/Km);
(2) binding constants for ligands (Kd) and capacity of receptor binding (Bmax);
(3) kinetic mechanism of a bi- or multi-substrate enzyme reaction;
(4) effect of buffer components, such as salts, metals and any inorganic/organic solvents and solutes on enzyme activity and receptor binding;
(5) kinetic isotope effect on enzyme catalyzed reactions;
(6) effect of pH on enzyme catalysis and binding;
(7) dose-response of inhibitor or activator on enzyme or receptor activity (IC50 and EC50 value);
(8) analysis of mechanism of inhibition of an enzyme catalyzed reaction and associated inhibition constants (slope inhibition constant (Kis) and intercept inhibition constant (Kii));
(9) equilibrium binding experiments to determine binding constants (Kd);
(10) determination of binding stoichiometry via a continuous variation method; and
(11) interaction of two inhibitors, two ligands or a ligand and an inhibitor by a method of continuous variation.
In some embodiments of the presently disclosed methods, a first reagent flows within a first fluid stream and the second reagent flows within a second fluid stream. Further, contacting the first and second reagents comprises flowing the first fluid stream into contact with the second fluid stream so as to merge the first and second fluid streams into a merged fluid stream. Further, in some embodiments, continuously varying the concentration of at least one of the first and second reagents comprises varying volumetric flow rates of the first and second fluid streams within a continuous-flow reaction system. Additionally, in some embodiments, varying the volumetric flow rates of the first and second fluid streams comprises controlling speeds of a first pump and a second pump which individually drive first and second fluid streams, respectively. The pumps can be in some embodiments displacement pumps. In some embodiments, the first and second pumps are synchronized to maintain overall constant volumetric flow rate while varying individual volumetric flow rates of the first and second fluid streams. Still further, in some embodiments of the presently disclosed methods, the continuous-flow reaction system is a fluidic system comprising a network of tubing in flow communication.
In some embodiments of the presently disclosed methods, the continuous-flow reaction system is a fluidic system, wherein the first and second fluid streams are merged via a same fluidic input. In some embodiments, the continuous-flow reaction system is a microfluidic device and in some embodiments, the first and second fluid streams flow within channels on a microfluidic chip, such as for example a microfluidic chip as described herein, including a microfluidic chip as encompassed by sample processing apparatus SPA described herein and illustrated in
In other embodiments of the method, the method further comprises contacting a third reagent with the first and second reagents, wherein the concentration of at least one of the first, second, and third reagents continuously varies with time. In some embodiments, the third reagent is a second substrate or ligand of the first reagent, whereas in other embodiments the third reagent is a proton, and in others, the third reagent is a reaction component varied to determine optimal reaction conditions, such as for example, buffers, co-factors, salts and salt concentrations, pH, etc.
In still further embodiments of the method wherein a third reagent is present, the first reagent flows within a first fluid stream, the second reagent flows within a second fluid stream, and the third reagent flows within a third fluid stream and contacting the first and second reagents comprises flowing the first fluid stream into contact with the second fluid stream so as to merge the first and second fluid streams into a first merged fluid stream and contacting the third reagent with the first and second reagents comprises flowing the third fluid stream into contact with the first merged fluid stream so as to merge the third fluid stream and the first merged fluid stream into a second merged fluid stream.
In some embodiments wherein a third reagent is present, continuously varying the concentration of at least one of the first, second, and third reagents comprises varying volumetric flow rates of the first, second, and third fluid streams within a continuous-flow reaction system. Further, in some embodiments, varying the volumetric flow rates of the first, second, and third fluid streams comprises controlling speeds of a first pump, a second pump, and a third pump which individually drive first, second, and third fluid streams, respectively. The first, second, and third pumps can be in some embodiments displacement pumps. The first and second pumps can be synchronized to maintain an overall constant volumetric flow rate of the first merged fluid stream while varying individual volumetric flow rates of the first and second fluid streams. The third pump can also be synchronized with the first and second pumps to produce an overall constant volumetric flow rate of the second merged fluid stream. In still further embodiments wherein a third reagent is present, the continuous-flow reaction system can be a fluidic system comprising a network of tubing in flow communication.
In some embodiments wherein a third reagent is present, the continuous-flow reaction system is a microfluidic device and the first, second, and third fluid streams flow within channels on a microfluidic chip, including for example, a microfluidic chip as encompassed by sample processing apparatus SPA described herein and illustrated in
The amount of data points and accuracy of collection for the above noted exemplary applications, when performed using the sample processing apparatus SPA described herein, are superior to that observed in any heretofore known data collection techniques. In particular, the sample processing apparatus SPA provides directly measurable continuous concentration gradients by accurately varying the volumetric flow rates of multiple reagent streams simultaneously by a precisely known amount. Therefore, it is known by direct observation what the expected concentration gradients are, rather than having to calculate the gradients indirectly. This allows for more accurate data collection than is possible with previously described devices for the applications listed above and others. The pump mechanisms described herein facilitate the use of continuous concentration gradients, in that in one embodiment, the pump mechanisms operate by flow displacement, which provides more precise volume control.
Referring now to
Generally, excitation source ES can be any suitable continuum or line source or combination of sources for providing a continuous or pulsed input of initial electromagnetic energy (hv)0 to detection point DP (
Wavelength selector WS2 is utilized as appropriate for the analytical technique being implemented, and can comprise one or more filters or monochromators that isolate a restricted region of the electromagnetic spectrum and provide a filtered signal (hv)2 for subsequent processing. Radiation detector RD can be any appropriate photoelectric transducer that converts the radiant energy of filtered analytical signal (hv)2 into an electrical signal I suitable for use by signal processing and readout device SPR. Non-limiting examples include photocells, photomultiplier tubes (PMTs), avalanche photodiodes (APDs), photodiode arrays (PDAs), and charge-coupled devices (CCDs). In particular, for fluorescence measurements, a PMT or APD can be operated in a photon counting mode to increase sensitivity or yield improved signal-to-noise ratios. Advantageously, radiation detector RD is enclosed in an insulated and opaque box to guard against thermal fluctuations in the ambient environment and keep out light.
Signal processing and readout device SPR can perform a number of different functions as necessary to condition the electrical signal for display in a human-readable form, such as amplification (i.e., multiplication of the signal by a constant greater than unity), phase shifting, logarithmic amplification, ratioing, attenuation (i.e., multiplication of the signal by a constant smaller than unity), integration, differentiation, addition, subtraction, exponential increase, conversion to AC, rectification to DC, comparison of the transduced signal with one from a standard source, and/or transformation of the electrical signal from a current to a voltage (or the converse of this operation). In addition, signal processing and readout device SPR can perform any suitable readout function for displaying the transduced and processed signal, and thus can include a moving-coil meter, a strip-chart recorder, a digital display unit such as a digital voltmeter or CRT terminal, a printer, or a similarly related device. Finally, signal processing and readout device SPR can control one or more other components of sample processing apparatus SPA as necessary to automate the mixing, sampling/measurement, and/or temperature regulation processes of the methods disclosed herein. For instance, signal processing and readout device SPR can be placed in communication with excitation source ES, pumps PA-PC and thermal control unit TCU via suitable electrical lines to control and synchronize their respective operations, as well as receive feedback from the encoders typically provided with pumps PA-PC.
As appreciated by persons skilled in the art, the signal processing, readout, and system control functions can be implemented in individual devices or integrated into a single device, and can be implemented using hardware (e.g., a PC computer), firmware (e.g., application-specific chips), software, or combinations thereof. The computer can be a general-purpose computer that includes a memory for storing computer program instructions for carrying out processing and control operations. The computer can also include a disk drive, a compact disk drive, or other suitable component for reading instructions contained on a computer-readable medium for carrying out such operations. In addition to output peripherals such as a display and printer, the computer can contain input peripherals such as a mouse, keyboard, barcode scanner, light pen, or other suitable component known to persons skilled in the art for enabling a user to input information into the computer.
Referring now to
Fluorescence measuring apparatus FMA can be configured such that multiple excitation wavelengths are simultaneously introduced into a sample containing multiple signal fluorophores inside microfluldic chip MFC. This can be done by using a multiple bandpass filter as a wavelength selector WS1 or by using multiple lasers as excitation light sources. Similarly multiple bandpass dichroic mirrors and multiple wavelength selectors WS2 can be used to transmit the fluorescence from individual fluorophores to multiple signal processing and readout devices SPR.
In the embodiment illustrated in
Referring to
Configuration module 52 enables a user to create individual volumetric flow profiles (see, e.g.,
Thermal control module 54 controls the operation of thermal control unit TCU (
Manual or debug module 56 can be used to manually control (including, for instance, overriding certain automated functions on an as-needed basis) any aspect of sample processing apparatus SPA. As examples, the user can control the flow rate of each pump PA, PB and PC individually, adjust the temperature settings of pumps PA-PC and microfluidic chip MFC, view in real time the values read by radiation detector RD, monitor any peripheral analog input devices such as photodiodes or thermistors, and the like.
Chip navigation module 58 is a tool for controlling the user's view of microfluidic chip MFC and events occurring therein during an experiment. For instance, chip navigation module 58 can allow the user to define an exact point or region of interest on microfluidic chip MFC and repeatably return to that point or region with the click of a button on the user interface, even after microfluidic chip MFC has been removed from and placed back on chip positioning or mounting stage (
Finally, run or data acquisition module actually executes the experiment according to the various user-defined parameters, including the flow velocity profiles designed using configuration module 52 and set point data inputted using thermal control module 54. Moreover, run or data acquisition module 60 can provide a display of information yielded during the course of the experiment, such as flow velocities and responses as described hereinabove with reference to
Referring now to
Referring to
In advantageous embodiments, pump assembly PA provides temperature-control functionality. While both heating and cooling can be effected, the ability to cool pump assembly PA is particularly advantageous as it enables thermally labile reagents to be cooled in-situ to prevent their degradation, thereby eliminating the need for ex-situ or on-chip refrigeration. Proteins, for example, can denature at room temperatures in a matter of hours. Thus, cooling is particularly important when lengthy run times are contemplated. For example, if a 10-μl barrel is used, approximately 8 hours of run time is possible at a flow rate of 20 nl/min. In one embodiment, pump assembly PA can maintain a reagent temperature ranging from approximately −4° C. to 70° C. to within 0.05° C. of accuracy. Moreover, thermal control of pump assembly PA provides the flow stability and noise reduction needed when operating at flow rates in the nl/min range. A change in room temperature can cause thermal expansion of the components of pump assembly PA that interact with the liquids being conveyed, thereby causing a thermal pumping effect. For example, when pumping at a low flow rate such as a few nl/min, a 1-nl change in the volume of the system (i.e., 0.01 percent of total volume for a 10 μl syringe pump) over one minute will be noticeable. Similarly, a 1° C. change in the temperature of the stainless steel plunger of some microsyringes causes the plunger to change length by 2 μm, changing the volume inside the microsyringe by 0.3 nl. Because room temperature is a disturbance, thermal pumping appears as noise in the output of the pumps of pump assembly PA. Hence, controlling the temperature of pump assembly PA reduces this noise. Finally, with regard to the multi-pump configuration illustrated in
As illustrated in
Temperature regulating element TRE1 is mounted between barrel holder 152 and heat sink 156 for either transferring heat to barrel holder 152 (and thus barrel and its fluid contents) or transferring heat away from barrel holder 152 to heat sink 156. In advantageous embodiments, temperature regulating element TRE1 is a thermoelectric device such as a Peltier device, as illustrated in
Referring to
Referring back to
Referring now to the respective exploded and assembly views of
Other components can be bonded to each other by using epoxy adhesive or any other suitable technique.
In the embodiment illustrated in
First annular member 202 has a bore 202A large enough to receive pump barrel 22. Hollow gasket 208 is sized to effect a fluid seal between pump barrel 22 and female fitting 210 when inserted into bore 202A of first annular member 202. Hollow gasket 208 is inserted far enough to abut the distal end of pump barrel 22, and has a bore 208A fluidly communicating with that of pump barrel 22 and aperture 210C of female fitting 210. In some embodiments, hollow gasket 208 is constructed from polytetrafluoroethylene (PTFE). Second annular member 204 is coaxially disposed about first annular member 202, and is removably secured thereto such as by providing mating threads on an outside surface 202B of first annular member 202 and an inside surface 204A of second annular member 204. Female fitting 210 is disposed within a cavity 206A of third annular member 206 and extends through a bore 206B of third annular member 206. The proximal end of female fitting 210, which can be defined by a flanged portion thereof, abuts the distal end of hollow gasket 208 and may abut the distal ends of first annular member 202 and/or second annular member 204. Female fitting 210 has a bore 210B beginning at a proximal aperture 210C disposed in axial alignment with bore 208A of hollow gasket 208. In the illustrated embodiment, at least a portion of bore 210B of female fitting 210 is tapered, and this tapered profile is complementary to a tapered profile presented by an outside surface 212A of male fitting 212 to effect a removable seal interface.
Third annular member 206 is coaxially disposed about second annular member 204, and is removably secured thereto such as by providing mating threads on an outside surface 204B of second annular member 204 and an inside surface 206C of third annular member 206. This feature enables third annular member 206 to be axially adjustable relative to second annular member 204 so as to bias hollow gasket 208 toward pump barrel 22, thereby improving the sealing interface of hollow gasket 208 between female fitting 210 and pump barrel 22. A sealing member 216, such as an annular gasket or o-ring, can be disposed in cavity 206A of third annular member 206 and is compressed between flanged portion of female fitting 210 and an inside surface 206D of cavity 206A, thereby improving the seal between the inside space of pump interconnect PI and the ambient environment by ensuring that the assembly of female fitting 210 and male fitting 212 sits flat against hollow gasket 208.
Male fitting 212 is inserted into bore 210B of female fitting 210, and has a bore 212B that is axially aligned with proximal aperture 210C of female fitting 210. In some embodiments, male fitting 212 is removably secured to female fitting 210 by providing mating threads on an outside surface 212C of male fitting 212 and an inside surface 210D of bore 210B of female fitting 210. Input line IL, provided for connection with microfluidic chip MFC as described hereinabove with reference to
Annular member 222 has a bore 222A large enough to receive pump barrel 22, and these two parts are glued together with epoxy such that a front face 22A of barrel 22 extends slightly beyond front face 222B of first annular member 222. Second annular member 206 is then screwed onto first annular member 222 engaging flanges 220A of female fitting 222 and forcing nipple 220C against the front face 22A of barrel 22 such that aperture 220B is in fluid communication with barrel bore 22B, and nipple 220C forms a pressure tight seal against front face 22A of barrel 22.
Referring now to
As illustrated in
Referring specifically to
In other advantageous embodiments, if cooling of microfluidic chip MFC is not necessary, temperature regulating element or elements TRE2 comprise resistive heating elements, which are readily commercially available and appreciated by persons skilled in the art. These can eliminate the need for heat sinks 262 and cooling fans 264. In one specific exemplary embodiment, shown in
Second thermally conductive body 254 can serve passively as a large thermal mass to limit temperature fluctuations and isolate microfluidic chip MFC from ambient air currents. The lower periphery of second body 254 can include an insulating layer 270 to thermally isolate second body 254 from any chip holder CH (
First body 252 is attached directly to second body 254 by any suitable means. Accordingly, thermal management of microfluidic chip MFC can be accomplished by operating temperature regulating devices to create temperature gradients directed either from first body 252 toward second body 254 (i.e., heating) or from second body 254 toward first body 252 (i.e., cooling), but should permit sufficient thermal contact between first body 252 and second body 254 to permit rapid dissipation of thermal gradients between the two, creating a nearly homogenous thermal environment for microfluidic chip MFC. The operation of chip temperature regulating device TRD2 can be controlled as described hereinabove regarding pump temperature regulating device TRD1, using the temperature control circuitry illustrated in
An alternate embodiment of the temperature regulating device TRD2 includes only a heat-producing device, comprising, for example, one or more heating elements mounted directly to or otherwise in thermal contact with microfluidic chip MFC, that is used to heat microfluidic chip MFC above ambient temperature. This permits microfluidic chip MFC to operate at the physiological range of many enzymes (e.g. 37° C.) and also accelerates the rate of enzyme action. In this embodiment, the ambient environment removes heat from the temperature regulating device TRD2 obviating any need for specialized heat dissipating components.
Connection of external pumps PA-PD to microfluidic chip MFC and to external components, such as switching valves and plate handlers as discussed below, requires the use of tubes or other conduits. These should be of minimal internal volume for efficient use of reagents, and their walls should have minimal compliance to avoid their behaving like a pressure “capacitor” in which the walls expand (and thus the internal volume increases) as pressure increases to drive fluid flows. Materials such as fused silica can be readily obtained as microcapillaries with small internal diameters and rigid walls. Additionally, the capillaries should be shielded from thermal fluctuations because thermal expansion of the capillaries will cause them to behave like thermal pumps, and oscillations in temperature will result in noise in the flows through these capillaries. Such shielding can be either an insulative wrap around the capillaries, or all components of the system, including the capillaries, can be housed in a single temperature-controlled enclosure.
Referring now to
Referring to
Referring to
In this embodiment, switching valve SV again has two positions (SV and SV′) and 6 or another number of ports as needed. Switching valve SV can permit the addition of only small amounts of reagent (sub-microliter) into a capillary 272 in between a pump PA, PB, PC or PD and microfluidic chip MFC, obviating the need to flush the pump PA, PB, PC or PD in between reagent changes. Reagents from multi-well plate MWP can be aspirated into a capillary 274 connected to switching valve SV. As appreciated by persons skilled in the art of automated liquid handling, the tip of capillary 274 can be carried on a motorized, programmable X-Y or X-Y-Z carriage or other robotic-type effector, permitting removal of reagent from any well in multi-well plate MWP. This capillary tip can be fitted with an independently actuated needle for piercing foil, plastic film or other types of septa used to seal the wells of multi-well plate MWP. Multi-well plate MWP can include 96 wells or another suitable number of wells. When injection loop INL is to be filled, the capillary 274 can be lowered into a well containing the fluid to be injected.
As shown in
When switching valve SV switches to position 2, one of pumps PA, PB, PC and PD can be connected through injection loop INL to microfluidic chip MFC. One of pumps PA, PB, PC and PD can advance fluid from injection loop INL through a corresponding capillary IA, IB, IC and ID into microfluidic chip MFC. Simultaneously, the carriage can move capillary 274 to a well of multi-well plate MWP having a rinsing fluid. Syringe pump SP can then repeatedly pull fluid into and then expel fluid from capillary 274 to rinse it clean.
Furthermore, syringe pump SP can be placed in communication with a three-way valve TWV, an external buffer reservoir BR, and a buffer loop BL (if additional buffer volume is needed or desired) to enable syringe pump SP to flush injection loop INL with buffer. Three-way valve TWV can permit refilling of syringe pump SP from buffer reservoir BR, preventing contamination of syringe pump SP and associated lines with any fluid from injection loop INL and the alternate fluid connection with buffer loop BL.
Referring to
Referring to
In the present, exemplary configuration, first switching valve SV1 has two primary positions (the first position designated SV1 and the second position designated SV′1) and second switching valve SV2 likewise has two primary positions (the first position designated SV2 and the second position designated SV′2). When both switching valves SV1 and SV2 are in their respective first positions, their corresponding pump of pump assembly (pump PD in the illustrated embodiment) fluidly communicates with an input of microfluidic chip MFC. At its second position, first switching valve SV′1 permits pump PD to draw additional reagent from reagent reservoir RR for refilling purposes. At its first position, second switching valve SV2 can fill injection loop INL with a reagent selected from multi-well plate MWP, or flush injection loop INL with buffer from the system comprising syringe pump SP, three-way valve TWV, external buffer reservoir BR, and buffer loop BL, as described hereinabove. At its second position, second switching valve SV′2 brings injection loop INL into fluid communication between pump assembly PA and microfluidic chip MFC, allowing the selected reagent residing in injection loop INL to be supplied to microfluidic chip MFC under the fine, precise control of the associated pump of pump assembly PA (pump PD in the illustration).
As described hereinabove, each component of the systems illustrated in
Carry-over can occur as different fluids are added into a microfluidic chip, such as microfluidic chip MFC shown in
To illustrate this carryover, experiments were conducted in which concentration gradients of fluorescent compounds were run against non-fluorescent buffer in a microfluidic chip MFC shown in
Carry-over in this exemplary system is believed to be generated by several factors: (1) large dead volumes in the switching valve SV (about 28 nl for the valves used), (2) large void or “unswept” volumes—outpockets from which contaminants enter or exit primarily by diffusion, and (3) moving parts which become “painted” by contaminating chemicals which only diffuse away very slowly. Thus, carry-over can be greatly reduced by removing moving parts, dead volumes, and void volumes from the fluidic system.
Carry-over can be eliminated or substantially reduced by utilizing the system described below including: (a) an on/off fluid freeze valve that has minimal dead volume, zero void volume, and no moving parts and, (b) an injection loop connected to the rest of the microfluidic system with interconnects having minimal dead volume and minimum void volume. According to one embodiment of a fluid freeze valve, the fluid freeze valve can change a capillary to an “off” state by lowering the temperature of fluid in the capillary such that the fluid reaches a solid or nearly solid state for stopping or substantially reducing the fluid flow through the capillary. Additionally, the system can increase the temperature of the frozen or nearly frozen fluid to return the capillary to an “on” state such that the fluid returns to a liquid state for allowing fluid flow through the capillary.
Referring to
Fluid freeze valves (such as fluid freeze valves FFVS shown in
Referring to
The collective resistance to flow generated by capillaries CP1, CP2, and CP3 and injection loop INL, combined with the pressure difference from the inlet to outlet of microfluidic chip MFC, can determine the volumetric flow rate. Thus, higher pressures can be generated at the inlet (capillary CP2) to increase volumetric flow rates. Driving flow by application of a vacuum to capillary CP1 during fluid changes in injection loop INL or to capillary CP3 during washes of the aging loop can limit the pressure difference to 15 pounds per square inch (p.s.i.) due to bubble formation via out-gassing of dissolved gases and cavitation of the fluid due to boiling at zero absolute pressure. Driving flow by pressurizing the inlet can generate higher pressure difference. In either case, flow metering device FMD on capillary CP1 can be used to meter the flow through capillary CP1 and, thus, injection loop INL, and this measurement can be used to determine when to turn off the pressure or vacuum to stop flow through the injection loop INL. Conversely, the flow rate through injection loop INL can be calculated, and the application of pressure or vacuum can be timed to control the volume that flows through injection loop INL. Placement of flow metering device FMD after on-chip injection loop INL removes any carry-over associated with metering device FMD from injection loop INL while still permitting accurate measurement of flow rates through injection loop INL.
Larger internal diameters for capillaries CP1, CP2, and CP3 can be used to decrease resistance and thus increase flow rates. Larger capillary diameters can also increase the volume of capillaries CP1, CP2, and CP3 which results in unwanted fluid waste. Additionally, larger capillary internal diameters can make the system more prone to noise in the flow rate introduced by fluctuating freeze-thaw at the edges of the freeze-valve as discussed above. Thus, increasing the pressure difference can generate more rapid flows and prevent unwanted increases in capillary diameters and noise. For the dimensions given above for capillaries CP1 and CP2 and for injection loop INL, with capillaries approximately 60 cm long, pressures up to 125 p.s.i. can be used to generate flow rates of 50 microliters/minute that push a volume equal to that of injection loop INL and capillary CP2 through injection loop INL in about 3 seconds for permitting rapid fluid exchanges. Higher pressures can permit more rapid fluid exchanges.
Pressurizing an inlet can increase the pressure through microfluidic system MS. If the entire system can withstand the increased pressure, then the higher pressures convey several advantages. Bubbles can sometimes be accidentally introduced into a microfluidic system, and pressurizing the inlet facilitates the removal of these bubbles. A higher pressure compresses bubbles, making it easier to flush the bubbles out of injection loop INL. The higher pressure can also increase the gas-carrying capacity of the fluid, accelerating the rate at which bubbles dissolve into the fluid and, thereby, more quickly removing bubbles that will not flush out.
Pressure-tight fittings can be utilized to create a seal around a multi-well plate (such as multi-well plate MWP shown in
Referring again to
Handling system 2300 can include pressure-tight seals at the following two locations: (1) a seal S1 can be positioned between input capillary IC and air pressure manifold APM for providing sealing as capillary IC moves within manifold APM; and (2) a seal S2 can be positioned between piercing needle PN and multi-well plate MWP. Seal S1 can be created by an air-lock nut ALN that can be a threaded screw through which a hole is drilled. The diameter of the hole in nut ALN can match the diameter of input capillary IC such that only a small gap remains for allowing capillary IC to slide through the air-lock nut ALN as second vertical translation stage VTS2 moves vertically. Seal S2 can be created by forcing needle PN into septum RS.
Referring to
Referring to
Referring to
Referring to
Alternatively, seal S2 can be formed as depicted in
Referring again to
According to some exemplary experiments, flows have been generated of 75 microliters per minute through the injection loop with pressures of 125 pounds per square inch in the multi-well plate. As described herein, the flow rate through the microfluidic chip is determined by the combined resistance to flow in the capillaries and microchannels. The total volume of flow through the system, which determines the degree of rinsing of the injection loop and the aging loop is then controlled by either modulating the pressure, modulating the total time that pressure is applied, or both. It is also possible to measure the flow through the outlet capillary (capillary CP1 in
As described above, flow through the on-chip injection loop can be driven by a vacuum at the output rather than a pressure at the input. While this limits the pressure difference to 15 pounds per square inch, it obviates the need for all of the special pressure-tight seals described above. The only pressure-tight seal needed is the seal between the outlet capillary and the vacuum container, and this seal need not be interrupted at any time during use of the microfluidic chip. The vacuum need only be vented and reapplied, which can be easily implemented with electrically-actuated switching valves in communication with the vacuum container.
In some instances, fluid in an injection loop (such as injection loop INL shown in
Referring specifically to
III.A. General Biochemistry Considerations
III.A.1. Enzyme Inhibitor Potency and Mechanism of Inhibition
Inhibitors of enzyme targets are often sought as part of the drug development process. The understanding of potency and mechanism of inhibition provides desirable information for progressing inhibitors into drugs. Enzyme reaction and inhibition kinetics are conventionally studied with the assumption that equilibria are achieved rapidly and thus the kinetics can be described by rate equations that assume a steady-state concentration of enzyme, substrate(s) and any other added ligand effectors (if their concentrations are greater than 10 fold higher than enzyme concentration). A comprehensive review of enzyme kinetics theory and enzyme inhibition mechanisms can be found in Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems; Segel, Irwin (1975) Wiley Interscience (ISBN: 0-471-30309-7), incorporated herein by reference.
Characterization of enzyme inhibition is generally discussed in terms of the three Michaelis-Menten reaction schemes shown below. A rate equation can be derived for each inhibition mechanism, which describes how the rate of product formation is decreased with increasing amounts of inhibitor.
An enzyme inhibition reaction in which an inhibitor (I) binds to an enzyme (E), to the exclusion of a substrate of the enzyme (S) is termed a “competitive” inhibition reaction and is illustrated by the reaction formula below. The competitive inhibition can be overcome by an excess concentration of substrate.
An enzyme inhibition reaction in which an inhibitor binds to an enzyme-substrate (ES), but not the enzyme alone is termed an “uncompetitive” inhibition reaction and is illustrated by the reaction formula below. In an uncompetitive inhibition reaction, the reaction rate is decreased by inhibitor binding to a site distant or separate from the substrate-binding site. The inhibition increases with increasing substrate concentration, as the concentration of ES is increased.
An enzyme inhibition reaction in which an inhibitor binds to both the free enzyme (E) and an enzyme-substrate complex (ES) is termed a “mixed” or “noncompetitive” inhibition reaction and is illustrated by the reaction formula below. The inhibitor binds to the free enzyme and to the enzyme-substrate complex with equal (noncompetitive inhibition) or unequal (mixed inhibition) affinities. Substrate binding may (mixed inhibition) or may not (noncompetitive inhibition) enhance the affinity of the inhibitor (i.e. Kii≠Kis or Kii=Kis, see term definitions below).
In conventional experimental and data fitting methods, inhibition mechanisms are identified by measuring the initial rate of the enzymatic reaction while independently and iteratively varying inhibitor and substrate concentrations, with every substrate and inhibitor concentration condition contained in a separate reaction solution (discontinuous data generation). The data from these orthogonal experiments are then fitted to Michaelis-Menten rate equations that describes one of the three inhibition mechanisms outlined above. More often, the data are fitted to the mixed inhibition rate equation (see the mixed/noncompetitive inhibition reaction formula above), shown below in Equation 1, which can discriminate between the mechanisms by the relative values of Kii and Kis yielded from the data fitting, which determine the relative affinities of inhibitor to E or ES or both. For a strictly competitive inhibitor, data fitting to this model would yield a reasonable number for Kis (competitive component), but an unreasonable value of Kii (uncompetitive component), while an uncompetitive inhibitor would yield the reverse: a reasonable Kii term (for binding to ES), but unreasonable Kis (no binding to free enzyme). Mixed or noncompetitive binding would yield values of Kii and Kis that are equal, or unequal but significant.
ν=Vmax*S/Km*(1+I/Kis)+S*(1+I/Kii) (Equation 1)
where:
ν=initial velocity of the reaction;
Vmax=maximal velocity;
S=concentration of interrogated substrate;
I=concentration of inhibitor;
Km=Michaelis constant for substrate;
Kis=slope inhibition constant; and
Kii=intercept inhibition constant
For example, the graphs in
As discussed above, in a conventional experiment (using microtiter plates) the substrate and inhibitor concentrations are varied independently, or orthogonally, such that each curve would require at least ten independent reaction solutions to fit unambiguously. Since all five curves are minimally required to pinpoint the mechanism and obtain Kii/Kis values, each inhibitor would require at least 50 independent reactions from which to obtain reaction rates, and ultimately the potency and mechanism of the inhibitor. A single enzyme drug discovery program normally requires the mechanism and potencies of 10 s, 100 s and even 1000 s of inhibitors at a time, representing up to 50,000 individual reaction wells to measure and analyze. Thus, using known methods discussed above to analyze potential modulators of enzymes (including enzyme inhibitors and activators) in a new drug-screening program creates issues related to amounts of reagents required and time needed to develop useful data.
III.A.2. Kinetic Mechanism of Bireactant Enzyme Systems
Inhibitors of enzyme targets can be identified from an analysis and understanding of the enzyme's chemical and kinetic mechanisms. Characterization of the enzyme mechanism often sheds light on how to best inhibit (or activate) the enzyme activity, which is then connected to the desired biological response in other studies. As discussed herein above, enzyme reaction and inhibition kinetics are conventionally studied with the assumption that equilibria are achieved rapidly. Thus, the kinetics can be described by rate equations that assume a steady-state concentration of enzyme, substrate(s) and any other added ligand effectors. The rate equation derived in Equation 1 is based on the uni-reactant kinetic mechanism presented for all three main types of inhibition. However, many enzyme targets have more than one substrate and product, and therefore have net rate equations that describe the additional binding and release steps.
Bireactant enzyme systems comprise two general kinetic mechanisms, ternary and ping-pong. A ternary mechanism describes a mechanism in which the enzyme and the two substrates form a unit complex before chemistry occurs, and a ping-pong mechanism is one in which a product forms and dissociates before the addition of the second substrate and release of the second product. A comprehensive review of enzyme kinetics theory describing bireactant mechanisms can be found in Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems; Segel, Irwin; (1975) Wiley Interscience; ISBN: 0-471-30309-7).
A classical ternary kinetic mechanism includes random or ordered addition of the multiple substrates to the enzyme to form an enzyme-substrate A-substrate B complex (EAB).
The formula below illustrates a kinetic scheme for a random ternary bireactant mechanism.
In contrast, the formula below illustrates a kinetic scheme for an ordered ternary bireactant mechanism.
Although mechanistically different, both types of ternary mechanisms can be described by Equation 2:
ν=Vmax*A*B/(Kia*Kb+Kb*A+Ka*B+A*B) (Equation 2)
where: f
ν=initial velocity of the reaction;
Vmax=maximal velocity;
A=concentration of substrate A;
B=concentration of substrate B;
Ka=Michaelis constant for substrate A;
Kb=Michaelis constant for substrate B; and
Kia=dissociation constant of substrate A.
A key feature of a classical ping-pong bireactant mechanism is that the enzyme (E) assumes an intermediate modified form (F) after binding a first substrate (A), distinct from the starting enzyme form. After releasing a first product (P), the modified enzyme form binds a second substrate (B), which results in the formation of a second product (Q) and the return of the enzyme to its starting form.
The formula below illustrates a kinetic scheme for a ping-pong bireactant mechanism.
The Ping Pong mechanism can be described by Equation 3:
ν=Vmax*A*B/(Kb*A+Ka*B+A*B) (Equation 3)
where:
Vmax=maximal velocity;
A=concentration of substrate A;
B=concentration of substrate B;
Ka=Michaelis constant for substrate A; and
Kb=Michaelis constant for substrate B.
As discussed above, the conventional discontinuous method of substrate concentration variation and data analysis requires a multitude of data sets to obtain enough data to unambiguously determine mechanism. Therefore, using prior art discontinuous methods to analyze kinetic mechanisms a bireactant enzyme system creates issues related to amounts of reagents required and time needed to develop useful data.
III.B. Determination of Enzyme Inhibitor Potency and Mechanism of Action
The presently disclosed subject matter provides methods for determining a mechanism of inhibition and/or potency of one or more inhibitors of a biological molecule. The known models and equations discussed in the General Considerations section herein above with respect to enzyme inhibitors are modified as disclosed herein below to provide applicable equations for interpreting data obtained by simultaneous and continuous variation of at least two components of the reaction system, including one or more inhibitors of the biological molecule and/or a substrate of the biological molecule.
Further, the presently disclosed novel methods of continuous variation of multiple variables can be extended to other enzymological/pharmacological methods including the Job plot method of determining binding stoichiometry and inhibitor synergy (see Huang, C. Y. (1982) Methods Enzymol. 87; 509-25 for review).
III.B.1 Single Inhibitor Systems
The methods of the presently disclosed subject matter described herein provide for determining the mechanism of inhibition and/or potency of an inhibitor of a biological molecule, such as for example an enzyme or receptor, by simultaneously and continuously varying the concentrations of at least one substrate of the biological molecule and an inhibitor of the biological molecule to obtain a far greater density of data than is possible using present methods utilizing discrete concentration gradients.
The mixed inhibition model (Equation 1) can be recast into one in which the interrogated substrate and inhibitor are co-varied around a constant ratio to one another (Equation 4). The model can be used universally to discriminate the three mechanisms of inhibitor action (competitive, noncompetitive and uncompetitive). The fractional gradient that describes this constant ratio of S relative to I concentration is introduced as a new independent variable, B, which in effect modifies each concentration term by this factor.
ν=Vmax*S*B/Km*(1+I*B/Kis)+S*B*(1+I*B/Kii) (Equation 4)
where:
ν=initial velocity of the reaction;
Vmax=maximal velocity;
S=concentration of interrogated substrate;
I=concentration of inhibitor;
Km=Michaelis constant for substrate;
Kis=slope inhibition constant; and
Kii=intercept inhibition constant.
As discussed in the General Considerations section herein above, the conventional method of data generation and analysis data fitted to the model can yield Kii and Kis values, which reveal potency and mechanism of the inhibitor, it can also yield ambiguous results. A critical control experiment is the condition in which inhibitor is lacking to obtain the Vmax and Km values. These values are used as fixed constraints in Equation 4.
Some representative advantages of the continuous method of S and I variation, over the conventional orthogonal method using independent reaction wells with discrete concentrations of S and I to determine inhibitor potency and mechanism are:
The definitive discrimination between the two mechanisms that produce a peak and decline curve (uncompetitive and noncompetitive inhibitors) is difficult from a low-density, limited precision, discontinuous dataset. This point is demonstrated in the Examples presented herein below, which compares data collection via a microtiter plate vs. a microfluidics system disclosed herein providing continuously variable concentration gradients for the same enzyme system, using the methodology described by the presently disclosed subject matter and data analysis available using Equation 4.
The method for determining a mechanism of inhibition and/or potency of an inhibitor of a biological molecule comprises contacting at least one inhibitor, a biological molecule, and at least one ligand for the biological molecule under conditions where concentrations of at least two of the at least one inhibitor, the biological molecule and the at least one ligand are simultaneously varied; and determining an outcome of the contacting of the at least one inhibitor, the at least one ligand, and the biological molecule to determine one of the mechanism of inhibition, potency of the inhibitor, and both the mechanism of inhibition and potency of the inhibitor.
In some embodiments, the biological molecule comprises an enzyme, such as for example lactate dehydrogenase, and the at least one ligand comprises a substrate of the enzyme, such as for example an enzyme inhibitor. In other embodiments, the biological molecule comprises a receptor and the at least one ligand comprises a receptor ligand. As a non-limiting example, 7-transmembrane receptors in general could be acceptable receptors for use with the methods of the presently disclosed subject matter. In some embodiments, the concentrations of the at least one inhibitor and the at least one ligand are simultaneously varied, and further, in some embodiments, the concentrations are simultaneously varied such that a ratio of the concentrations is held constant. That is, for example, in some embodiments as the concentration of either the ligand or inhibitor is increased, the concentration of the other component is proportionately decreased. Thus, in embodiments where the concentrations of components are varied by varying the flow rates of the fluid streams through which the components flow, the total flow rate of the combined fluid streams remains the same, even as the flow rate of each stream varies proportionately with the other fluid stream. Examples 3 and 4 herein below further illustrate this embodiment in detail.
In some embodiments of the presently disclosed subject matter, the concentrations are simultaneously varied with discrete concentration gradients. The discrete concentration gradients can in some embodiments be contained within discrete containers, which can be for example, wells in a microtiter plate. In other embodiments, the concentrations are simultaneously varied with continuous concentration gradients. The continuous concentration gradients can be formed in some embodiments, for example, using a microfluidic system comprising a microfluidic chip. In some preferred embodiments, the microfluidic system comprises a system as described herein below.
Further, in some embodiments, determining the outcome of contacting together at least one inhibitor, at least one ligand and the biological molecule, which can for example be an enzyme or receptor, comprises an inhibition constant of the at least one inhibitor. The determined inhibition constant can be the inhibition constant of the at least one inhibitor with regard to biological molecule and/or the inhibition constant of the at least one inhibitor with the biological molecule-ligand complex. For example with regard to enzyme inhibitors, a slope inhibition constant (Kis) and/or an intercept inhibition constant (Kii) can be determined as the outcome of contacting at least one inhibitor, at least one ligand, and a biological molecule. The inhibition constants can be determined using Equation 4, for example, as described above. These calculations are further of value in determining the mechanism of inhibition and/or the potency of the inhibitor. For example, the mechanism of inhibition determined can be a determination of whether the inhibitor acts by a competitive, non-competitive, uncompetitive or mixed mechanism of inhibition. Further, determining the potency of the inhibitor can, for example, comprise determining the IC50 of the inhibitor with regard to the particular biological molecule and ligand.
III.B.2. Dual Inhibitor Systems
The methods of the presently disclosed subject matter described herein provide for determining the interaction with each other of two inhibitors of the same biological molecule, by simultaneously and continuously varying the concentrations of the inhibitors of the biological molecule with regard to each other to obtain a far greater density of data than is possible using present discrete concentration gradients.
A general equation describing dual inhibition can be reformulated into one in which the two inhibitors are co-varied around a constant ratio to one another (Equation 5). The methods described herein can be used to identify whether inhibitors are synergistic, antagonistic, or neutral with respect to each other. The fractional gradient describing this constant ratio of inhibitor 1 relative to inhibitor 2 is introduced as the independent variable, B, which in effect modifies each concentration term by this factor.
ν=Vmax*S/(Km*(1+I1*B/Ki1+I2*B/Ki2+(I1*I2*B)/(α*Ki1*Ki2))+S*(1+I1*B/Ki1+I2*B/KI2+(I1*I2*B)/(α*Ki1*Ki2))) (Equation 5)
where:
ν=initial velocity of the reaction
Vmax=maximal velocity
S=concentration of interrogated substrate
I1=concentration of inhibitor 1
I2=concentration of inhibitor 2
Km=Michaelis constant for substrate
Ki1=Inhibition constant for inhibitor 1
KI2=Inhibition constant for inhibitor 2
α=interaction factor
The representative advantages provided by the novel methods disclosed herein for determining potency and mechanism of action for a single inhibitor system apply as well to the novel continuous method of dual inhibitor variation, over the conventional orthogonal method using independent reaction wells with discrete concentrations. The precise high density data provided by the methods of the presently disclosed subject matter provide greater accuracy in determining type of inhibitor interaction using fewer reagents, over a shorter period of time, and permitting greater automation than conventional techniques.
As with reactions having a single inhibitor analyzed using the presently disclosed subject matter, reactions comprising two inhibitors suspected to inhibit the same biological molecule can be analyzed using methods disclosed herein. In some embodiments, the methods comprise contacting a biological molecule, at least one ligand of the biological molecule, and two inhibitors suspected of being capable of inhibiting the biological molecule, under condition wherein concentrations of at least two of the biological molecule, the at least one ligand, and the two suspected inhibitors are simultaneously varied, and determining an outcome of the contact.
In some embodiments, the concentrations of the two inhibitors and/or the at least one ligand are simultaneously varied, and further, in some embodiments, the two inhibitors and/or the at least one ligand are simultaneously varied such that a ratio of the concentrations is constant.
In some embodiments, determining an outcome of the contact between a biological molecule, at least one ligand of the biological molecule, and two inhibitors suspected of being capable of inhibiting the biological molecule comprises determining an interaction factor (α) of the interaction between the two inhibitors. The interaction factor can be calculated, for example, utilizing Equation 5. Determining the interaction factor permits for determination of whether the two inhibitors are synergistic, antagonistic or neutral with respect to each other.
III.C. Determination of Enzyme Activator Potency and Mechanism of Action
The presently disclosed subject matter provides methods for determining a mechanism of activation and/or potency of an activator of a biological molecule. The methods of the presently disclosed subject matter described herein provide for determining the mechanism of activation and/or potency of an activator of a biological molecule, such as for example an enzyme or receptor, by simultaneously and continuously varying the concentrations of at least one substrate of the biological molecule and at least one activator of the biological molecule to obtain far greater data density than is possible using present discrete concentration gradients. The known models and equations discussed in General Considerations and Section II herein above with respect to enzyme inhibitors are further modified as disclosed herein below to provide applicable equations for interpreting data obtained by simultaneous and continuous variation of at least two components of the reaction system.
The model presented above in Section II for inhibitors (Equation 4) can be extended for use in reactions comprising biological molecule activators in which substrate and activator are simultaneously and continuously varied. The formula below illustrates a general kinetic scheme describing a nonessential activation mechanism.
A general equation describing nonessential activation was recast into one in which the interrogated substrate and activator are co-varied around a constant ratio to one another for use with methods of the presently disclosed subject matter (Equation 6). This model can also be used universally to discriminate between activators that are effectors of Vmax, Km, or both. The fractional gradient that describes this constant ratio of concentration S relative to concentration A is Introduced as the independent variable, B, which in effect modifies each concentration term by this factor.
ν=Vmax*S*B/(Km*(1+β(A*B/Kact)/(1+β(A*B/α*Kact))+(S*B*(1+(A*B/α*Kact))/(1β(A*B/α*Kact))) (Equation 6)
where:
ν=initial velocity of the reaction
Vmax=maximal velocity
S=concentration of interrogated substrate
A=concentration of activator
Km=Michaelis constant for substrate
Kact=Activation constant for activator
α and β=activator interaction factors on Km, Kact, and Vmax
As with methods disclosed herein for use in determining mechanism of action and/or potency of inhibitors, similar representative advantages exist over conventional methodology when using the novel methods of the presently disclosed subject matter as applied to characterizing reactions comprising activators of biological molecules.
In some embodiments, methods described herein for determining a mechanism of activation and/or potency of an activator of a biological molecule comprises contacting at least one activator, a biological molecule, and at least one ligand for the biological molecule under conditions where concentrations of at least two of the at least one activator, the biological molecule and the at least one ligand are simultaneously varied; and determining an outcome of the contacting of the at least one activator, the at least one ligand, and the biological molecule to determine the mechanism of activation, potency of the activator, or both the mechanism of activation and potency of the activator.
In some embodiments, the biological molecule comprises an enzyme and the at least one ligand comprises a substrate of the enzyme, such as for example an enzyme activator. In other embodiments, the biological molecule comprises a receptor and the at least one ligand comprises a receptor ligand.
In some embodiments, the concentrations of the at least one inhibitor and the at least one ligand are simultaneously varied, and further, in some embodiments, the concentrations are simultaneously varied such that a ratio of the concentrations is held constant. That is, for example, as the concentration of either the ligand or inhibitor is increased, the concentration of the other component is proportionately decreased. Thus, in embodiments where the concentrations of components are varied by varying the flow rates of the fluid streams through which the components flow, the total flow rate of the combined fluid streams remains the same, even as the flow rate of each stream varies proportionately with the other fluid stream. Examples 3 and 4 herein below further illustrate this embodiment in detail. In some embodiments of the presently disclosed subject matter, the concentrations are simultaneously varied with discrete concentration gradients. The discrete concentration gradients can in some embodiments be contained within discrete containers, which can be for example, wells in a microtiter plate. In other embodiments, the concentrations are simultaneously varied with continuous concentration gradients. The continuous concentration gradients can be formed in some embodiments, for example, using a microfluidic system comprising a microfluidic chip. In some preferred embodiments, the microfluidic system comprises a system as described herein below.
Further, in some embodiments, determining the mechanism of activation of an activator comprises determining an activation constant for the activator (Kact), which is described in detail above and can be calculated, for example, utilizing Equation 6. Further, in some embodiments, determining the potency of the activator comprise determining at least one activator interaction factor affecting a Michaelis constant for the ligand (Km) and/or a maximal velocity (Vmax). Equation 6 can further be utilized, as described above, to calculate Km and Vmax to determine activator potency.
III.D. Determination of Bisubstrate Enzyme System Kinetic Mechanism
The presently disclosed subject matter provides methods for determining a mechanism of reaction and/or kinetic constants of ligands of a bireactant biological molecule system. The methods of the presently disclosed subject matter described herein provide for determining mechanism of reaction and/or kinetic constants of ligands of a bireactant biological molecule system by simultaneously and continuously varying the concentrations of at least two of a biological molecule, such as for example an enzyme or receptor molecule, and a plurality of ligands of the biological molecule, thereby obtaining far greater data density than is possible using present discrete concentration gradients.
The known mechanism models and equations discussed in Section I herein above with respect to bireactant enzyme systems (Equations 2 and 3) are further modified by the presently disclosed subject matter methods as disclosed herein below to provide applicable equations for interpreting data obtained by simultaneous and continuous variation of at least two components of a bireactant substrate/ligand reaction system. The models discussed in Section I (Equations 2 and 3) for all types of bireactant kinetic mechanisms described above can be collated into one of two equations, for use with a planar dataset with simultaneous continuous variation of two substrates.
The novel methods disclosed herein provide at least two methods of presenting the modified model.
Method 1 presents data as a concentration of substrate A and introduces a ratio constant of concentration of substrate B/concentration of substrate A, as demonstrated by Equation 7a:
ν=Vmax*x*A2/(Kia*Kb+Kb*A+Ka*X*A+x*A2) Equation 7a
where:
Vmax=maximal velocity;
A=concentration of substrate A;
B=concentration of substrate B;
Ka=Michaelis constant for substrate A;
Kb=Michaelis constant for substrate B;
Kia=dissociation constant of substrate A; and
x=ratio constant where x=[B]/[A].
Method 2 presents data as a fraction gradient of a constant ratio of substrates A and B, as demonstrated by Equation 7b:
ν=Vmax*A*B*G/(Kia*Kb+Kb*A*G+Ka*A*G+A*B*G) Equation 7b
where:
Vmax=maximal velocity;
A=concentration of substrate A;
B=concentration of substrate B;
Ka=Michaelis constant for substrate A;
Kb=Michaelis constant for substrate B;
Kia=dissociation constant of substrate A; and
G=fraction gradient of constant ratio of A and B.
In some embodiments, methods for determining one of a mechanism of reaction, kinetic constants of ligands, and both a mechanism of reaction and kinetic constants of ligands of a bireactant biological molecule system are provided. The methods comprise in some embodiments, contacting a biological molecule and a plurality of ligands for the biological molecule under conditions where concentrations of at least two of the biological molecule and plurality of ligands are simultaneously varied and determining an outcome of the contacting of the biological molecule and the plurality of ligands to determine one of the mechanism of reaction, the kinetic constants of the ligands, or both the mechanism of reaction and the kinetic constants of the ligands of the bireactant biological molecule system.
In some embodiments, the concentrations of the plurality of ligands are each simultaneously varied. Further, in some embodiments, the concentrations of the plurality of ligands are each simultaneously varied such that a ratio of the concentrations is constant. That is, for example, as the concentration of either the ligand or inhibitor is increased, the concentration of the other component is proportionately decreased. Thus, in embodiments where the concentrations of components are varied by varying the flow rates of the fluid streams through which the components flow, the total flow rate of the combined fluid streams remains the same, even as the flow rate of each stream varies proportionately with the other fluid stream.
In some embodiments of the methods, the biological molecule can comprise an enzyme and the plurality of ligands can each comprise a substrate of the enzyme. Further, determining the kinetics constants of the enzyme substrates in these embodiments can comprise determining the Michaelis constant (Km) for at least one of the enzyme substrates. The Km for at least one of the enzyme substrates can be determined by application of the experimental data to either Equation 7a or 7b, as described above. Further, in some embodiments, the Km can be determined for both substrates. For example, the Km for a first substrate A (Ka) can be determined and the Km for a second substrate B (Kb) can be determined simultaneously utilizing either Equation 7a or 7b.
In other embodiments, the biological molecule can comprise a receptor and the plurality of ligands can each comprise a ligand of the receptor. Further, determining the kinetics constants of the receptor ligands in these embodiments can comprise determining the dissociation constant for at least one of the receptor ligands utilizing either Equation 7a or 7b.
In some embodiments of the method, the concentrations are simultaneously varied with discrete concentration gradients. Further, in some embodiments, each of the discrete concentrations can be contained in discrete containers. The discrete containers can be wells in a microtiter plate. In other embodiments, the concentrations are simultaneously varied with continuous concentration gradients. The continuous concentration gradients can be in a microfluidic chip. In some preferred embodiments, the microfluidic system comprises a system as described herein below.
Adsorption of a molecule to the wall of a microfluidic channel can sometimes present a problem in microfluidic and other miniaturized systems in which the ratio of surface area to volume is many orders of magnitude larger than is found in more conventional approaches, such as for example, dispensing and mixing of solutions in microtiter plates. Adsorption of molecules in microfluidic systems and other miniaturized devices can be a major obstacle to miniaturization as the adsorption can affect molecule concentrations within fluids, thereby negatively impacting data collected from the microfluidic systems or other miniaturized devices. Adsorption driven changes in concentration can be especially problematic for microfluidic systems used to generate concentration gradients.
In some embodiments, the presently disclosed subject matter provides apparatuses and methods for using the same that can decrease the interference of adsorption to concentration dependent measurements, such as in biochemistry reactions including IC50 determinations, by altering the geometry of a microfluidic channel. Although adsorption may not be eliminated, the change in concentration caused by adsorption can be minimized. In general terms, the effects of adsorption on measurements can be minimized by reducing the ratio of channel surface area to fluid volume within the channel (S/V), which also increases diffusion distances. However, as a high surface area to volume ratio can be an unavoidable consequence of the miniaturization of microfluidics, the geometries provided by some embodiments of the presently disclosed subject matter to minimize adsorption consequences are most unexpected by persons in the field of microfluidics. The presently disclosed subject matter provides for, in some embodiments, using large channel diameters in regions of the microfluidic chip most affected by adsorption of reaction components, that is, in regions where a reaction proceeds and/or where measurements are taken. In some embodiments of the presently disclosed subject matter, and with reference to the microfluidic chip embodiment shown in
Turning now to
A consequence of increasing analysis channel AC cross-section by increasing channel diameter is that the ratio of channel surface area to fluid volume (S/V) within the channel is decreased, relative to a narrower channel. For example, to measure a reaction 3 minutes after mixing, with a volumetric flow rate of 30 mL/min, the reaction should be measured at a point in the channel such that a microfluidic channel section spanning from mixing point MP to detection area DA encloses 90 nL. For an analysis channel with a square cross-section and a diameter of 25 μm, this point is about 144 mm downstream from mix point MP. This channel has a surface area of 1.44×10−5 square meters, yielding a surface to volume ratio S/V equal to 1.6×105 m−1. For a channel with a diameter of 250 μm, the measurement is made 1.44 mm downstream from mix point MP. This wider channel has a surface area of 1.44×10−6 square meters, yielding a S/V equal to 1.6×104 m−1, which is 1/10th the S/V of the narrower channel. This alone can decrease ten-fold the removal of compound per unit volume by adsorption.
This geometry change can also decrease the radial diffusive flux of compound. Flow in these small channels is at low Reynolds number, so diffusion from a point in the fluid is the only mechanism by which compound concentration changes radially in a microfluidic channel. Increasing the radius of the channel, thereby decreasing the radial diffusive flux, therefore, means that the concentration of compound at center analysis region CR of analysis region AR can be less affected by adsorption than in the smaller upstream channels.
Thus, increasing the cross-sectional area of analysis region AR of analysis channel AC can both decrease the amount of adsorption at the wall per unit volume and decrease the rate of flux of compound from center analysis region CR to any of channel walls W. Both together mean that the concentration at center analysis region CR can decrease more slowly due to adsorption of compound.
Further, in all embodiments, the surface area of all channels exposed to compounds, not just analysis channel AC, can preferably be kept minimal, especially those channels through which concentration gradients flow. This can be accomplished by making channels as short as practicable. Additionally, when the volume contained by a channel must be defined (e.g. where the channel must contain a volume of 50 nL), it is best to use larger diameters/shorter lengths wherever possible to reduce S/V.
Another benefit of increasing analysis channel AC cross-section by increasing channel diameter is that the length of the channel down which the fluid flows can be reduced. In the example given earlier, a channel with 25 μm diameter needed to be 144 mm long to enclose 90 nl whereas the channel with 250 μm diameter needed to be only 1.44 mm long. This shorter channel can be much easier to fabricate and has a much smaller footprint on a microfluidic chip.
Still another benefit of increasing analysis channel AC cross-section is that it will behave like an expansion channel, which filters noise out of chemical concentration gradients, as disclosed in co-pending, commonly owned U.S. Provisional Application entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING NOISE GENERATED BY MECHANICAL INSTABILITIES, U.S. Provisional Application No. 60/707,245 (Attorney Docket No. 447/99/3/2), herein incorporated by reference in its entirety. The result is that signal to noise is larger in an analysis channel AC with larger cross-section.
Analysis channel AC can approximate a circular cross-section as closely as possible to produce the smallest ratio of surface area to volume, and also to produce the largest diffusion distance from centerline center analysis region CR to a channel wall W. However, microfluidic channels may not be circular in cross-section due to preferred manufacturing techniques. Rather, they can be more likely square in cross-section, with the exact shape depending on the technique used to form the channels. For such channels, a cross-section of analysis channel AC, particularly within analysis region AR, can have an aspect ratio as close to one as possible or, more precisely stated, the distance from center analysis region CR to channel wall W can be as nearly constant in all radial directions as possible.
Additional details and features of analysis channel AC are disclosed in co-pending, commonly owned U.S. Provisional Application entitled METHODS AND APPARATUSES FOR REDUCING EFFECTS OF MOLECULE ADSORPTION WITHIN MICROFLUIDIC CHANNELS, U.S. Provisional Application No. 60/707,366 (Attorney Docket No. 447/99/8), herein incorporated by reference in its entirety.
In some embodiments, the presently disclosed subject matter provides apparatuses and methods for making and using the same that can decrease the interference of adsorption to concentration dependent measurements, such as in biochemistry reactions (including IC50 determinations), by reducing adsorption of molecules to microfluidic channel walls. In some embodiments, the presently disclosed subject matter provides microfluidic chips comprising channels and chambers with treated surfaces exhibiting reduced adsorption of molecules to channel walls, such as for example hydrophilic surfaces, and methods of preparing and using the same. In some embodiments, methods of preparing hydrophilic surfaces by treating hydrocarbon-based plastics, such as for example polycarbonate, with fluorine gas mixtures are provided. In some exemplary embodiments, the methods comprise contacting a mixture of fluorine gas and an inert gas with the surface to be treated, then flushing the surface with air. This treatment results in plastic surfaces of increased hydrophilicity (increased surface energy). Hydrophobic solutes, in particular known and potential drug compounds, in solutions in contact with these treated hydrophilic plastic surfaces are less likely to be adsorbed onto the more hydrophilic surfaces. Plastics comprising the treated surfaces are useful in providing many improved drug discovery and biochemical research devices for handling, storing, and testing solutions containing low concentrations of hydrophobic solutes.
Additional details and features of hydrophilic surfaces in microfluidic systems and methods of making and using the same are disclosed in co-pending, commonly owned U.S. Provisional Application entitled PLASTIC SURFACES AND APPARATUSES FOR REDUCED ADSORPTION OF SOLUTES AND METHODS OF PREPARING THE SAME, U.S. Provisional Application No. 60/707,288 (Attorney Docket No. 447/99/9).
Further, in some embodiments of the presently disclosed subject matter, microfluidic systems are provided comprising an analysis channel with an enlarged cross-sectional area and a reduced surface area to volume ratio and further comprising channels and chambers with hydrophilic surfaces.
The following Examples have been included to illustrate representative modes of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the spirit and scope of the presently disclosed subject matter.
The inhibition mechanism of oxalate with respect to the substrate NAD+ yields an uncompetitive profile as deduced from conventional orthogonal analysis (see Lien L V, Ecsedi G, Keleti T. (1979) Acta Biochim Biophys Acad Sci Hung. (1-2); 11-17).
Determination of the mechanism of inhibition by the inhibitor oxalate with respect to the substrate NAD+ against the enzyme rabbit muscle lactate dehydrogenase (LDH) using a microtiter plate to generate individual step concentration gradients was attempted.
As
An attempt to determine the mechanism of inhibition by the inhibitor oxalate with respect to the substrate lactate against the enzyme rabbit muscle LDH using a microtiter plate to generate individual step concentration gradients was attempted.
The results from Examples 1 and 2 demonstrate that data from microtiter plates is too coarse to determine the mechanism of inhibition of an inhibitor with certainty. Although a competitive mechanism of inhibition can be presumed with some systems, distinguishing noncompetitive from uncompetitive inhibition is not possible unless the variance in the data is kept very small. In contrast, as demonstrated below, the novel methods disclosed herein utilizing a continuous variation of the ratio, B, produces high-resolution data, permitting determination of potency and discrimination of inhibitor mechanisms, including discriminating noncompetitive from uncompetitive inhibition mechanisms.
A fluorescence-coupled enzyme assay was developed using a microfluidics system described herein for creating a continuously variable concentration gradient to monitor the reduction of NAD+ by the enzyme LDH to give a fluorescent end product. This system was then adapted to measure potency and determine mechanism of inhibition by various inhibitors of LDH.
One of the products of the reaction in the assay, NADH, is coupled to Thermus thermophilus NADH oxidase to generate H2O2, which in turn is coupled to horseraddish peroxidase which reacts with NADH and amplex red (Molecular Probes, Inc., Eugene, Oreg., U.S.A.) to give the fluorescent product resorufin. Catalase-coated agarose beads were used as a scrubbing system to minimize any extraneous source of H2O2. In addition, as a general rule, the experimental design for the assay solutions was configured so as to minimize any variability of the non-variable reagents. A protocol for titration of LDH with NAD+ is shown in Table 1. A simple modification of the protocol in Table 1 is made for determining the mechanism of inhibition and potency of the inhibitors. Specifically, the inhibitor at the desired maximum 2× concentration is added to solution 2.
The protocol for generating the gradient on the microfluidics system is outlined in Table 2. The linear gradient is formed between pumps 1 and 2 (see for example,
The novel data analysis techniques described herein for determining the mechanism of inhibition of an inhibitor (or mechanism of activation of an activator) are applied to the data produced from the microfluidics system. The titration of the enzyme with a continuous linear variation of inhibitor and substrate from zero to a pre-determined finite concentration yields a characteristic rate profile that is defined by the specific type of interaction of the inhibitor and enzyme with respect to the substrate. The data is fitted to the novel mixed inhibition equation described herein above (Equation 4) using GraFit™ (Erithacus Software Limited, Surrey, United Kingdom):
ν=Vmax*S*B/Km*(1+I*B/Kis)+S*B*(1+I*B/Kii),
where Vmax represents maximum velocity, S is the varied substrate concentration, I is the varied inhibitor concentration, Km is the Michaelis constant, B is the fraction composition of the gradient, K is the slope inhibition constant, and Kii is the intercept inhibition constant. In order to minimize the number of parameters for robust curve fitting, the non-linear fitting program was written to accept a constant value for Km. In addition, the B term allows the user to enter finite S and I values for the maximum substrate and inhibitor concentrations, respectively. The floating parameters are Vmax, Kis and Kii.
Most enzymes studied to date exhibit Michaelis-Menten saturation kinetics with their respective substrate(s) and yield a characteristic hyperbolic rate profile. The titration of LDH with a linear gradient of NAD+ was performed on the microfluidics system described herein with the change in relative fluorescence intensity monitored under initial rate conditions. The data were fitted to the Michaelis-Menten equation and the Km value determined from the microfluidics system (54±2 μM) are shown to conform to that obtained on a microtiter plate.
The system was next tested with several different inhibitors of LDH to experimentally determine the potency and mechanism of action of the inhibitors using a continuously variable concentration gradient of the inhibitors created by the microfluidics system. Data from these experiments are provided below in Examples 3-5.
A small molecule inhibitor (GW409578X identified from a high-throughput screening campaign of a chemical library against LDH was interrogated against the substrates NAD+ and lactate to validate the continuously variable concentration gradient method created by the microfluidics system and the ability to faithfully reproduce the kinetic mechanism of inhibition using the novel methods described herein.
The data graphed in
The diagnostic curves obtained for each experiment are mechanistically correct and yield accurate inhibition constants as compared with that determined via conventional analysis. It is also worth noting that the mechanism of inhibition determined for lactate vs. GW409578X using conventional analysis (a continuous 6×6 ‘grid’ technique) yielded a Kis value of 17+/−4 μM, which is a 24% standard error. Thus, the presently disclosed novel methods using a continuous concentration gradient provided more accurate data and used fewer reagents. The robustness of the novel methods described herein results in part from obtaining a large volume of high precision data throughout the duration of the continuous gradient.
A microfluidics device as described herein was used to create a continuously variable concentration gradient of the inhibitor oxalate with regard to the substrate NAD+ against the enzyme Plasmodium falciparum LDH to experimentally determine the mechanism of inhibition.
From this Example, in comparison with Examples 1 and 2, it can be seen that the presently disclosed subject matter provides for the capability of determining a mechanism of action and potency of an inhibitor of an enzyme with great accuracy, in contrast to known methods which require more reagents and provide less reliable data.
To illustrate carryover and how it affects a microfluidics system, experiments were conducted in which concentration gradients of fluorescent compounds were run against non-fluorescent buffer in a microfluidic chip MFC shown in
For this experiment, the autosampling system depicted in
The switching valve SV was placed into Position 1 and capillary 274 was moved to the well containing the fluorescent solution. The injection loop INL was then filled with fluorescent solution by syringe pump SP, as described herein above. The switching valve SV was then changed to Position 2, placing the fluorescent solution-filled injection loop INL in line with pump PD. The flow from microfluidic pumps PB, PC, and PD was as follows:
After the gradient of fluorophores was run, the injection loop INL and capillary 274 were thoroughly rinsed by syringe pump SP. Capillary 272 and microfluidic chip MFC were flushed with buffer from all three microfluidic pumps PB, PC, and PD. For all flushes, a volume minimally equivalent to 4 times the system volume were flushed through the respective portions of the system. All pumps stopped, and capillary 274 was moved to the buffer-only well on the multiwell plate (MWP), and the injection loop INL was filled with buffer. Gradients were then again run, identical to the ones above. Given the thorough flushing of the system, there should have been no fluorophore remaining anywhere in the system. Any fluorescence detected is, therefore, fluorescent compound carryover. The fluorescence measured by the system is shown in
Carry-over in this system is believed to be generated by several factors: (1) large dead volumes in the switching valve SV (about 28 nl for the valves used), (2) large void or “unswept” volumes—outpockets from which contaminants enter or exit primarily by diffusion, and (3) moving parts which become “painted” by contaminating chemicals which only diffuse away very slowly. Thus, carry-over can be greatly reduced by removing moving parts, dead volumes, and void volumes from the fluidic system.
Carry-over can be reduced or eliminated through implementation of the measures discussed herein above.
It will be understood that various details of the subject matter disclosed herein may be changed without departing from the scope of the subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
This application claims the benefit of U.S. Patent Application Ser. No. 60/707,370, filed Aug. 11, 2005, the disclosure of which is incorporated herein by reference in its entirety. The disclosures of the following U.S. Provisional Applications, commonly owned and simultaneously filed Aug. 11, 2005, are all incorporated by reference in their entirety: U.S. Provisional Application entitled MICROFLUIDIC APPARATUS AND METHOD FOR SAMPLE PREPARATION AND ANALYSIS, U.S. Provisional Application No. 60/707,373 (Attorney Docket No. 447/99/2/1); U.S. Provisional Application entitled APPARATUS AND METHOD FOR HANDLING FLUIDS AT NANO-SCALE RATES, U.S. Provisional Application No. 60/707,421 (Attorney Docket No. 447/99/2/2); U.S. Provisional Application entitled MICROFLUIDIC BASED APPARATUS AND METHOD FOR THERMAL REGULATION AND NOISE REDUCTION, U.S. Provisional Application No. 60/707,330 (Attorney Docket No. 447/99/2/3); U.S. Provisional Application entitled MICROFLUIDIC METHODS AND APPARATUSES FOR FLUID MIXING AND VALVING, U.S. Provisional Application No. 60/707,329 (Attorney Docket No. 447/99/2/4); U.S. Provisional Application entitled METHODS AND APPARATUSES FOR GENERATING A SEAL BETWEEN A CONDUIT AND A RESERVOIR WELL, U.S. Provisional Application No. 60/707,286 (Attorney Docket No. 447/99/2/5); U.S. Provisional Application entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING DIFFUSION AND COMPLIANCE EFFECTS AT A FLUID MIXING REGION, U.S. Provisional Application No. 60/707,220 (Attorney Docket No. 447/99/3/1); U.S. Provisional Application entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING NOISE GENERATED BY MECHANICAL INSTABILITIES, U.S. Provisional Application No. 60/707,245 (Attorney Docket No. 447/99/3/2); U.S. Provisional Application entitled MICROFLUIDIC SYSTEMS, DEVICES AND METHODS FOR REDUCING BACKGROUND AUTOFLUORESCENCE AND THE EFFECTS THEREOF, U.S. Provisional Application No. 60/707,386 (Attorney Docket No. 447/99/3/3); U.S. Provisional Application entitled MICROFLUIDIC CHIP APPARATUSES, SYSTEMS, AND METHODS HAVING FLUIDIC AND FIBER OPTIC INTERCONNECTIONS, U.S. Provisional Application No. 60/707,246 (Attorney Docket No. 447/99/4/2); U.S. Provisional Application entitled METHODS FOR CHARACTERIZING BIOLOGICAL MOLECULE MODULATORS, U.S. Provisional Application No. 60/707,328 (Attorney Docket No. 447/99/5/1); U.S. Provisional Application entitled METHODS AND APPARATUSES FOR REDUCING EFFECTS OF MOLECULE ADSORPTION WITHIN MICROFLUIDIC CHANNELS, U.S. Provisional Application No. 60/707,366 (Attorney Docket No. 447/99/8); U.S. Provisional Application entitled PLASTIC SURFACES AND APPARATUSES FOR REDUCED ADSORPTION OF SOLUTES AND METHODS OF PREPARING THE SAME, U.S. Provisional Application No. 60/707,288 (Attorney Docket No. 447/99/9); U.S. Provisional Application entitled BIOCHEMICAL ASSAY METHODS, U.S. Provisional Application No. 60/707,374 (Attorney Docket No. 447/99/10); U.S. Provisional Application entitled FLOW REACTOR METHOD AND APPARATUS, U.S. Provisional Application No. 60/707,233 (Attorney Docket No. 447/99/11); and U.S. Provisional Application entitled MICROFLUIDIC SYSTEM AND METHODS, U.S. Provisional Application No. 60/707,384 (Attorney Docket No. 447/99/12).
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US06/31171 | 8/10/2006 | WO | 00 | 5/16/2007 |
Number | Date | Country | |
---|---|---|---|
60707370 | Aug 2005 | US |